<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS206122</article-id><article-id pub-id-type="doi">10.1101/2025.05.27.656322</article-id><article-id pub-id-type="archive">PPR1029203</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Early Radiation Therapy Response Assessment using Multi-scale Photoacoustic Imaging</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lefebvre</surname><given-names>Thierry L.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Oraiopoulou</surname><given-names>Mariam-Eleni</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bunce</surname><given-names>Ellie V.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Else</surname><given-names>Thomas R.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wright</surname><given-names>Lorna C.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Golinska</surname><given-names>Monika A.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hacker</surname><given-names>Lina</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Brodie</surname><given-names>Cara</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kupczak</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Yi</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sweeney</surname><given-names>Paul W.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bohndiek</surname><given-names>Sarah E.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Physics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution></institution-wrap>, <addr-line>JJ Thomson Avenue</addr-line>, <city>Cambridge</city>, <postal-code>CB3 0HE</postal-code>, <country country="GB">UK</country></aff><aff id="A2"><label>2</label>Cancer Research UK Cambridge Institute, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>University of Cambridge</institution></institution-wrap>, <addr-line>Robinson Way</addr-line>, <city>Cambridge</city>, <postal-code>CB2 0RE</postal-code>, <country country="GB">UK</country></aff><aff id="A3"><label>3</label>Department of Oncology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap>, Roosevelt Drive, <city>Oxford</city>, <postal-code>OX3 7DQ</postal-code>, <country country="GB">UK</country></aff><author-notes><corresp id="CR1">Correspondence: <email>seb53@cam.ac.uk</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>04</day><month>06</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>31</day><month>05</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">CC BY-NC 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">There is a critical unmet clinical need to identify biomarkers that predict and detect radiotherapy response in cancer. Using the unique capabilities of multi-scale photoacoustic imaging (PAI) for depicting tumour oxygenation and vasculature <italic>in vivo</italic>, we identified surrogate biomarkers of radiation response in two human breast cancer models (MCF7 and MDA-MB-231), comparing hypofractionated delivery with an ablative single dose scheme. <italic>Ex vivo</italic> immunohistochemistry results underpinned findings from mesoscopic and multispectral tomographic PAI, performed 24h pre-RT, 24h post-RT, and at endpoint. A denser and more mature vasculature of the MCF7 xenografts afforded an improved response to both RT schemes compared to MDA-MB-231, in terms of overall tumour oxygenation, tumour volume and proliferation. Increased intratumoural blood oxygen saturation and oxygen diffusion pre-RT were associated with improved outcomes and decreased proliferation, expected given the oxygen-enhancement effect in RT. <italic>In vivo</italic> PAI revealed the differential effect between ablative courses of RT in both models, with the ablative scheme altering the tumour vasculature as early as 24h post-RT, and pruning the looping vessels and total blood volume at endpoint in the more radiosensitive MCF-7 xenografts. An increase in blood oxygen saturation at endpoint was observed only in the MCF7 xenografts treated with hypofractionated RT, confirming the reduced oxygen consumption of damaged tumour cells, indicative of response. Thus, we showed that PAI could capture early RT response and inform on radioresistance, thus demonstrating promise of PAI as an <italic>in vivo</italic> and future clinical tool to monitor the tumour vascular response to RT.</p></abstract><kwd-group><kwd>photoacoustic imaging</kwd><kwd>radiation therapy</kwd><kwd>radiation oncology</kwd><kwd>breast cancer</kwd><kwd>treatment response</kwd><kwd>medical image analysis</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Hypoxia is a common phenotype in many solid tumours. Uncontrolled cellular proliferation is metabolically demanding, yet the nascent tumour vasculature is often chaotic and poorly supported, leading to inadequate delivery and distribution of oxygen in the growing tumour mass(<xref ref-type="bibr" rid="R1">1</xref>). Hypoxia and the associated overexpression of hypoxia-related proteins is frequently associated with tumour aggressiveness, particularly in hormone-dependent cancers such as breast cancer, and poor treatment outcomes, for example, in radiation therapy (RT) (<xref ref-type="bibr" rid="R2">2</xref>–<xref ref-type="bibr" rid="R4">4</xref>). A particular use-case that intersects these two challenges is the application of neoadjuvant RT in breast cancer treatment, which has shown promise for invasive and locally advanced breast cancer to enable improved resectability and breast-conserving surgery (<xref ref-type="bibr" rid="R5">5</xref>–<xref ref-type="bibr" rid="R8">8</xref>), and is currently being investigated in clinical trials (ClinicalTrials.gov ID, NCT05479409, NCT05216900, and NCT05412225). In low lineal energy transfer (LET) RT such as X-ray-based therapies, the dose of radiation required to achieve the same biological effect in hypoxic regions is up to 3-fold higher than in normoxic regions (<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R10">10</xref>). Nonetheless, tumour oxygen distribution is typically not assessed or considered clinically during treatment planning even with RT as a first-line treatment in many solid tumours (<xref ref-type="bibr" rid="R11">11</xref>), let alone in the neoadjuvant setting.</p><p id="P3">With the trend towards hypofractionation, <italic>i.e.</italic> fewer fractions of higher dose using delivery methods such as stereotactic body/ablative RT (SBRT/SABR), hypoxia becomes a more critical consideration as the tumour microenvironment does not benefit as much from the inter-fraction reoxygenation in conventional RT schemes (<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R13">13</xref>). Real-time visualisation of the spatial distribution of intratumoural hypoxia is necessary to enable dose painting for hypofractionation schemes (<xref ref-type="bibr" rid="R14">14</xref>). Furthermore, in ablative courses of RT prescribed with higher dose per fraction (&gt;16 Gy), endothelial cells lining the vasculature will undergo apoptosis and contribute to the tumour response (<xref ref-type="bibr" rid="R15">15</xref>–<xref ref-type="bibr" rid="R17">17</xref>). Damage to endothelial cells can be mediated through acid sphingomyelinase-dependent and p53-independant membrane alterations, leading to ceramide upregulation and apoptotic signaling, which could acutely exacerbate hypoxia, worsening outcomes specifically through the vascular response to SBRT/SABR (<xref ref-type="bibr" rid="R18">18</xref>–<xref ref-type="bibr" rid="R20">20</xref>).</p><p id="P4">The clinical value of imaging in the neoadjuvant RT setting is well established for predicting and assessing treatment response (<xref ref-type="bibr" rid="R21">21</xref>, <xref ref-type="bibr" rid="R22">22</xref>); however, it has yet to account for the impact of hypoxia (<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R24">24</xref>). Positron emission tomography (PET) tracers like fluoromisonidazole (<sup>18</sup>FMISO) could be used to map tumour hypoxia (<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R27">27</xref>), but adding radiation dose is undesirable for longitudinal imaging. Magnetic resonance imaging (MRI) can determine microcirculatory properties through blood-or tissue-oxygen level dependent signals (<xref ref-type="bibr" rid="R28">28</xref>, <xref ref-type="bibr" rid="R29">29</xref>), define sub-volumes for radiation dose escalation based on diffusion (<xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R31">31</xref>) and identify perfusion imaging biomarkers (<xref ref-type="bibr" rid="R32">32</xref>, <xref ref-type="bibr" rid="R33">33</xref>). Nonetheless, these techniques are constrained by limited spatio-temporal resolution and often require the use of exogenous contrast agents, which comes with costs and potential toxicity concerns (<xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R35">35</xref>). Considering the spatio-temporal heterogeneity of hypoxia and angiogenesis in the tumour microenvironment (<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R36">36</xref>, <xref ref-type="bibr" rid="R37">37</xref>), any solution applied in the neoadjuvant setting would need to be low-cost, easy to use at the bedside, and provide high resolution data for immediate interpretation.</p><p id="P5">In this study, we demonstrate the potential of photoacoustic imaging (PAI) as a solution to these key challenges in radiation oncology (<xref ref-type="bibr" rid="R38">38</xref>, <xref ref-type="bibr" rid="R39">39</xref>), demonstrating its value in providing predictive biomarkers, enabling early response monitoring, and visualisation of vascular remodelling. PAI leverages optical contrast for mapping different tissue chromophores at depth by overcoming the optical diffusion limit through ultrasound detection of acoustic relaxation waves. The characteristic high optical absorption contrast of oxy-and deoxy-haemoglobin is ideally suited for visualising perfused vasculature and quantifying tumour blood oxygenation (<xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R41">41</xref>). PAI can be applied tomographically at high temporal resolution or at higher spatial resolution with raster-scanning modes (<xref ref-type="bibr" rid="R42">42</xref>, <xref ref-type="bibr" rid="R43">43</xref>). Previous studies have shown the ability of PAI to capture RT and chemo-RT response in preclinical models separately using these distinct PAI modes (<xref ref-type="bibr" rid="R44">44</xref>–<xref ref-type="bibr" rid="R46">46</xref>). However, each examined only part of the roles of the vasculature and tumour oxygenation in the RT response picture. Here, by holistically combining tomographic and mesoscopic PAI, we undertook a longitudinal investigation to establish the potential of quantitative PAI biomarkers to assess vascular morphology and function in two preclinical breast cancer models at 24h before RT treatment, 24h after, and at endpoint (1 week after) with hypofractionated and ablative schemes. Using a thorough immunohistochemistry (IHC) analysis of the models, we demonstrate that PAI captures changes in vascular morphology, including vessel looping structures, alongside intratumoural oxygenation dynamics, which together predict response to treatment, define the early response to treatment and confirming response at endpoint. PAI could therefore play a future role in profiling radiosensitivity, treatment planning and verification, as well as confirming treatment response in the neoadjuvant and adjuvant settings.</p></sec><sec id="S2" sec-type="materials | methods"><title>Materials and Methods</title><p id="P6">A schematic overview of the study design can be found in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p><sec id="S3"><title><italic>In vitro</italic> cell line preparation</title><p id="P7">Two human breast adenocarcinoma cell lines were selected as part of this study: MCF7, a luminal A subtype with estrogen and progesterone receptors positive, and human epidermal growth factor receptor 2 (HER2) negative (ER+, PR+, HER2-), and MDA-MB-231, a triple negative (ER-, PR-, HER2-) mesenchymal stem-like basal B subtype invasive ductal carinoma (<xref ref-type="fig" rid="F1">Figure 1A</xref>). The models exhibit differential response to RT <italic>in vitro</italic> (survival fraction at 2 Gy of 0.70-0.82 in MDA-MB-231 cell cultures and 0.40-57 in MCF7 cell cultures (<xref ref-type="bibr" rid="R47">47</xref>–<xref ref-type="bibr" rid="R50">50</xref>)) and when implanted as xenograft models give distinct intratumoural hypoxic and vascular features for <italic>in vivo</italic> PAI (<xref ref-type="bibr" rid="R51">51</xref>) <xref ref-type="fig" rid="F1">Figure 1B,C</xref>). Human cell lines were obtained from the local biorepository of the Cancer Research UK Cambridge Institute at the University of Cambridge, UK. Cells were used only between passages 25-27 (MCF7) or 35-37 (MDA-MB-231). At the start of the study, short tandem repeat (STR) profiling showed 100% match with reference sequences in the two cell lines. Cell lines were passaged and maintained separately in Roswell Park Memorial Institute (RPMI) 1640 Medium (RPMI 1640, Gibco, ThermoFisher Scientific) supplemented with 10% of Foetal Bovine Serum (FBS, Gibco, ThermoFisher Scientific) at 37°C in 5% CO<sub>2</sub>, never exceeding 80% confluence.</p></sec><sec id="S4"><title>Animal models</title><p id="P8">Scientific procedures on small animals were performed under the authority of project (PE12C2B96) and personal licenses issued by the Home Office, UK, under the Animals (Scientific Procedures) Act, 1986, and were reviewed for compliance by the local Animal Welfare and Ethical Review Board (compliance form CFSB2226) at the Cancer Research UK Cambridge Institute. All procedures were conducted following the latest guidance on animal welfare (<xref ref-type="bibr" rid="R52">52</xref>). Well-being was monitored daily by animal technicians and study conductors. Animals were housed in sterile conditions within hermetic individually ventilated cages with efficiency particulate air filtration, on 12h on/12h off light cycles, and were provided with free access to irradiated sterile food (Mouse Diet 20 Extruded 5R58, PicoLab) and water.</p><p id="P9">After habituation, subcutaneous cell implantations were performed in the location of the mammary fat pad in eight-week-old immunodeficient female BALB/C nude mice (BALB/c nu/nu, Charles River) (<xref ref-type="fig" rid="F1">Figure 1D</xref>). Cell lines were tested for absence of mycoplasma contamination prior to animal implantation. Inoculations of 1 × 10<sup>6</sup> cells were prepared in a 50 μL solution with a 1:1 ratio of basement membrane extract (Cultrex BME, PathClear, R&amp;D Systems, Bio-Techne) and phosphate-buffered saline (PBS, Gibco, ThermoFisher Scientific), kept on ice. For the ER+ cell line (MCF7) tumour-bearing mice, estrogen pellet implantations (E2-M 17<italic>β</italic>-estradiol 90-day implants, Belma Technologies) were conducted 48h prior to inoculations by surgically implanting a single pellet in the scruff of the neck of animals according to recent protocols (<xref ref-type="bibr" rid="R53">53</xref>). When tumours reached a measurable size (&gt; 3 mm in diameter), calliper measurements and animal weighing were performed up to 3 times per week for monitoring tumour growth and animal health. Diameter was measured in the two major orthogonal axes of the growing mass, <italic>a</italic>, the smallest axis, and <italic>b</italic>, the largest axis, and tumour volume, <italic>V</italic>, was calculated as <italic>V</italic> = <italic>ab</italic><sup>2</sup><italic>π/</italic>6. Humane endpoints were defined as: i) tumour reaching over 1.5 cm in average diameter; ii) a weight loss surpassing 15% of enrolment weight; iii) acute clinical signs of ill health such as lack of movement, distress, and poor body score; iv) skin conditions such as moist desquamation or bleeding ulceration; and v) in hormone supplemented animals, persistent skin lesions or bladder calcification. During treatment, if signs of weight loss were observed, dietary supplementation in the form of recovery gel (ClearH<sub>2</sub>O DietGel Recovery, Datesand Group) could be provided to animals for their demonstrated value in supporting recovery (<xref ref-type="bibr" rid="R54">54</xref>). If hormone supplementation related adverse effects were observed in MCF7-tumour bearing xenografts, animals were closely monitored up to twice a day, applying skin cream (DermaGel) and/or providing bladder massages to facilitate urine passage and limit the potential development of calcification, in consultation with the local named veterinary surgeon.</p></sec><sec id="S5"><title>Dosimetric quality assurance and treatment delivery optimisation of the preclinical image-guided irradiator</title><p id="P10">Prior to conducting any <italic>in vivo</italic> experiments, dosimetric quality assurance of the small animal radiation research platform (SARRP, Xstrahl) was performed to ensure that the planned dose corresponded to the actual delivered dose in tissue-equivalent phantoms (solid-water mass density (g/cm<sup>3</sup>), 1.032 ± 0.005; electron density (<italic>e</italic><sup>-</sup>/cm<sup>3</sup>), 0.557 ± 0.001; Sun Nuclear). Dose verification was performed with a National Physical Laboratory-calibrated ionisation chamber (Farmer, PTW Dosimetry) in standard solid-water phantoms in reference conditions (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1</xref>). The American Association of Physicists in Medicine (AAPM) protocol for 40–300 kV X-ray beam dosimetry was followed (<xref ref-type="bibr" rid="R55">55</xref>), using AAPM task group 51 formalism and the measured absolute dose was compared to the reference dose rate of 3.28 Gy/min measured at the initial SARRP commissioning (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>). It is recommended that differences between prescribed dose and delivered dose be 5% or less (<xref ref-type="bibr" rid="R56">56</xref>). Hence, each of the steps including treatment planning should introduce uncertainties under 5% and should add up to a maximum of 5%. In preclinical RT, even though we aim to reduce errors as low as reasonably achievable, higher uncertainties are typically tolerated, with maximal dose output differences of 10% (<xref ref-type="bibr" rid="R57">57</xref>). Differences to consider between preclinical and clinical RT are summarised in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref>.</p><p id="P11">Finally, prior to treatment, fixed beam delivery was compared to moving arc delivery after manually segmenting tumours and surrounding tissue or organs at risk (OAR) as two distinct instances on CBCT images, and resulting dose-volume histograms were assessed (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figures 2 and 3</xref>). This testing was conducted considering that preclinical irradiators are typically used solely in a top-irradiation fixed set-up. With the improved capabilities of image-guided irradiators, we were provided with the ability to give more conformal treatment and briefly attempted to show the added value of using the SARRP’s abilities through image guidance and moving arc delivery. All dosimetric verification results are provided in the <xref ref-type="supplementary-material" rid="SD1">Supplementary Note 1</xref>. The implementation of a quality assurance protocol confirmed the suitability of our preclinical RT framework described in the following subsection.</p></sec><sec id="S6"><title>Radiation therapy planning and delivery</title><p id="P12">All preclinical image-guided RT experiments were conducted using the small animal radiation research platform (SARRP, Xstrahl) mirroring clinical RT standards (<xref ref-type="bibr" rid="R58">58</xref>). RT was delivered under X-ray cone-beam computed tomography (CBCT) guidance in the local TG-61-calibrated SARRP with moving arcs optimised to target tumours and spare healthy tissue (<xref ref-type="bibr" rid="R55">55</xref>). For imaging guidance, CBCT were reconstructed in commercial treatment planning software (Muriplan, Xstrahl) from acquisitions of 360 projections at one-degree increments in imaging mode (peak energy, 60 kVp; beam filtration, 2.0 mm Al; maximum tube current, 2.8 mA; focal spot size, 0.4 mm; <xref ref-type="fig" rid="F1">Figure 1E</xref>). During treatment planning, a single moving arc spanning 130 degrees was centred on the tumour using CT guidance and the motorised beam collimator size was conformed to the tumour volume (between 7-10mm in both axes). Dose was calculated on the planning software using a superposition–convolution dose engine (<xref ref-type="bibr" rid="R59">59</xref>, <xref ref-type="bibr" rid="R60">60</xref>) and delivered on the SARRP using treatment mode at a dose rate of ≈ 2 Gy/min (peak energy, 225 kVp; beam filtration, 0.15 mm Cu; maximum tube current, 13.0 mA; focal spot size, 3.0 mm). Dose distributions were calculated on heterogeneous electron densities obtained from manual intensity thresholding on CBCT, assuming water density for all soft tissues, bone density for bones, and air for regions outside the animal. Source-to-axis distance (centre of the tumour) was fixed and bed positioning and total duration of X-ray delivery were adjusted based on dose calculation from the treatment planning software. Mice were enrolled onto a treatment course of one of the two selected biologically-equivalent RT schemes, when tumours reached a volume of 400 mm<sup>3</sup>: single dose RT (SDRT) of 20 Gy, tested recently in multiple clinical trials in breast cancer patients (<xref ref-type="bibr" rid="R61">61</xref>–<xref ref-type="bibr" rid="R65">65</xref>), or hypofractionated RT (HFRT) of 25 Gy in 5 fractions of 5 Gy, mirroring the dose fractionation of recent clinical trial in breast cancer patients (<xref ref-type="bibr" rid="R66">66</xref>) but in a neoadjuvant context (<xref ref-type="fig" rid="F1">Figure 1D-F</xref>). Tumour-bearing mice from the MCF7 model (<italic>n</italic> = 23) and MDA-MB-231 (<italic>n</italic> = 23) were blindly randomised into control or treated groups (Control, <italic>n</italic> = 13; SDRT, <italic>n</italic> = 18; HFRT, <italic>n</italic> = 15). Enrolled animals treatment and imaging data summaries are provided in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>.</p></sec><sec id="S7"><title><italic>In vivo</italic> photoacoustic imaging</title><p id="P13"><italic>In vivo</italic> tumour imaging was conducted in anaesthetised mice using mesoscopic (RSOM; Explorer P50, iThera Medical GmbH) and tomographic (MSOT; inVision, iThera Medical GmbH) PAI systems 24h pre-RT, 24h post-RT and at endpoint (mean time after treatment, 7 ± 3 days) for all mice. Prior to imaging, anaesthesia was induced in animals using 3% isoflurane in a gaseous mix of 50% medical air and 50% pure oxygen. Mice were then transferred to the mesoscopic PAI system on a heated bed kept at 37°C in supine position. Breathing was monitored and maintained between 70-80 breaths per minute, decreasing anaesthetic concentration to 1.5-2% isoflurane after induction, and maintained throughout imaging. The transducer head was manually positioned on the tumour region and coupled to the skin surface using warmed centrifuged ultrasound gel (Aquasonic Clear, Parker Laboratories Inc.). After careful removal of any residual air bubbles, raster-scanning acquisitions were conducted in a 12 x 12 mm<sup>2</sup> field of view at 20 μm step size, with 3 ns-long laser pulses of 80 mJ in energy at 1 kHz pulse repetition rate, synchronised with ultrasound detection using a single-element transducer with a centre frequency of 50 MHz (≈ 90% bandwidth). The total scan time for mesoscopic PAI was ≈7 min.</p><p id="P14">Anaesthetised animals were then moved to the tomographic PAI system animal holder and a membrane coupled to their skin with warmed ultrasound gel. Prior to acquisition, mice were placed in the tomographic PAI system, then stabilised and acclimatised in the system’s water bath maintained at 36°C for ten minutes. Tomographic acquisitions were performed on the largest tumour cross-section with 6 averages per wavelength (700, 730, 750, 760, 770, 800, 820, 840, 850 and 880 nm). A breathing-gas challenge was performed during tomographic PAI: time-resolved scans were acquired during 5 min on medical air (21% O<sub>2</sub>), after which the breathing gas was switched to pure oxygen (100% O2) for another 5 min as described previously (<xref ref-type="bibr" rid="R42">42</xref>) (exemplar quantified images in breathing gas challenge in <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 4</xref>). The total scan time for tomographic PAI including the gas challenge was ≈20 min. For pre-RT and post-RT scans, mice were slowly recovered in a heated chamber until active and inquisitive. After the endpoint scan, mice were euthanised with a recognised Schedule 1 method and death was confirmed prior to surgical tumour resection for histopathological processing.</p></sec><sec id="S8"><title>Photoacoustic image analysis and quantitative imaging biomarkers extraction</title><p id="P15">All image analyses were conducted in Python 3.9. Motion corrected mesoscopic PAI were reconstructed in 3D using a beam-forming algorithm (<xref ref-type="bibr" rid="R67">67</xref>, <xref ref-type="bibr" rid="R68">68</xref>). Images captured the tumour vasculature in a 12 × 12 mm<sup>2</sup> field of view and up to a depth of 4 mm, with in-plan resolution 20 × 20 μm<sub>2</sub> and axial resolution of 4 μm. Mesoscopic photoacoustic images were segmented using the vessel segmentation generative adversarial network (VAN-GAN) (<xref ref-type="bibr" rid="R69">69</xref>). Hand-drawn regions of interest (ROI) were selected on <italic>Z</italic>-slices throughout the reconstructed segmented 3D images by an experienced user (LCW), avoiding skin vessels and artefacts, using intensity images for quality assurance verifications. All tumour ROIs were validated by an expert user (TLL). Segmented vascular networks were skeletonised and the total blood volume (BV, μm<sup>3</sup>), the number of perfused vascular connected components (CC, representing the number of sets of vertices connected by path in the vascular skeleton), the vessel segments density (μm<sup>-3</sup>), the average diameters (μm), and the count of looping structures normalised to blood volume (loops, representing a collection of vertices connected by edges in the vascular skeleton forming a path closed on itself, μm<sup>-3</sup>) were extracted as quantitative imaging biomarkers, using previously reported software packages (<xref ref-type="bibr" rid="R70">70</xref>, <xref ref-type="bibr" rid="R71">71</xref>) (mesoscopic PAI metrics summary provided in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 4</xref>).</p><p id="P16">Using the Python photoacoustic tomography analysis toolkit (PATATO) (<xref ref-type="bibr" rid="R72">72</xref>), averaged PAI tomography images were reconstructed using a back-projection algorithm with in-plane resolution of 75 x 75 μm<sup>2</sup> at each acquired wavelength. Spectral image series were then downsampled to a resolution of 225 x 225 μm<sup>2</sup> to increase the signal-to-noise ratio and pixel-wise unmixing was conducted across wavelengths using oxy-and deoxy-haemoglobin absorption spectra. Tumour ROIs were manually selected on the largest tumour cross-section by two experienced users (LCW, TLL). A small ROI around a portion of the large femoral artery was also captured to identify changes in blood oxygenation as a reference. Resulting oxy-and deoxy-haemoglobin parametric maps were quantified in manually delineated tumour and reference ROIs to extract mean total haemoglobin (THb), blood oxygen saturation (sO<sub>2</sub>), and the standard deviation (SD) of sO<sub>2</sub>. We make a note that PAI-derived sO<sub>2</sub> reported throughout this manuscript is an estimate and not a direct interrogation of true/absolute blood oxygen saturation. Gas challenge tomographic data was analysed using sO<sub>2</sub> time-series data, identifying the time-point of change to pure oxygen in the reference region selected in the large femoral artery, to quantify and report the change in sO<sub>2</sub> (ΔsO<sub>2</sub>) under gas challenge in the tumour, and the responding fraction (RF) corresponding to the ratio of voxels with ΔsO<sub>2</sub> greater than one standard deviation above the baseline (before gas change) mean sO<sub>2</sub> (tomographic PAI metrics summary provided in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 4</xref>).</p></sec><sec id="S9"><title><italic>Ex vivo</italic> histopathological analysis</title><p id="P17">Excised tumours were processed, and formalin-fixed paraffin-embedded (FFPE) sections were taken for immunohistochemical (IHC) staining and analysis. Briefly, after excision, tumours were fixed in 10% formalin for 24h, and then moved to 70% ethanol for 48h. Resected tumours were then embedded in paraffin, sectioned, and rehydrated. IHC was performed using an automated stainer (BOND, Leica Biosystems) with a bond polymer refine detection kit and 3,3’-diaminobenzadine as a substrate. Tissue sections were stained for endothelial cell marker CD31, smooth muscle cell marker <italic>α</italic>-smooth muscle actin (ASMA), cellular proliferation nuclear marker Ki67, phosphorylated histone nuclear marker of DNA damage <italic>γ</italic>-H2AX, and hypoxia-inducible pro-angiogenic factor marker HIF1-<italic>α</italic> (antibody vendor, dilution and retrieval method provided in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 5</xref>). Adjacent 3 μm serial sections were used for CD31 and ASMA staining. Haematoxylin and Eosin (H&amp;E) staining was performed using an automated system (ST5020 Leica, Biosystems). Stained FFPE sections were scanned at 20× magnification using an Aperio AT2 with a resolution of 0.5 x 0.5 μm<sup>2</sup> (Leica Biosystems).</p><p id="P18">Analyses were conducted within the whole viable tumour area, excluding skin and necrotic regions, identified on H&amp;E. In HALO (v3.2, Indica Labs), random-forest classifiers were trained by an expert user (C.B.) for distinguishing between the necrotic and viable tissue regions. Classifiers were trained using at least 50 annotations per tissue class per image on a training set of 20-40% of the images and created independently for each stain and then applied across the scanned stained sections. Positive areas of CD31 and ASMA were quantified as a percentage of the total classified tumour area using the area quantification module (v2.4.3). The percentage of positive cells within the classified tumour regions were quantified for Ki67, <italic>γ</italic>-H2AX, and HIF1-<italic>α</italic> with the multiplex IHC module (v3.1.4). To quantify ASMA coverage of CD31-positive tumour vasculature, the CD31 random forest classifier was overlaid onto the ASMA section and its classifier, taking the intersection of the areas as the ASMA vessel coverage, and was reported as a percent of the total viable tumour area (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 5</xref>).</p></sec><sec id="S10"><title>Statistical analysis</title><p id="P19">All statistical analyses were conducted using the open-source Pingouin (v0.5.5) and statsmodels (v0.14.3) packages in Python 3.9. Descriptive statistics of the distribution of PAI and IHC biomarkers were computed and visualised with point and bar plots using the seaborn Python package (seaborn, v0.13.2). Unpaired non-parametric two-tailed Mann-Whitney <italic>U</italic> test was used for comparing <italic>in vivo</italic> and <italic>ex vivo</italic> imaging biomarkers between groups and conditions with Holm-Bonferonni multiplicity correction (<italic>m</italic> = 5 comparisons, within tumour model, between control and treated arms, and between controls across models) (<xref ref-type="bibr" rid="R73">73</xref>). Bivariate correlations between continuous variables extracted from <italic>in vivo</italic> PAI and <italic>ex vivo</italic> classified IHC regions were assessed with Pearson correlation coefficients, with associated Holm-Bonferonni-adjusted <italic>P</italic>-values. Quantitative imaging biomarkers measured at the different analysed time-points of interest across mice and conditions were analysed as continuous variables with linear mixed effects (LME) models, using as fixed effects the following categorical variables: tumour model (MCF7 or MD-MB-231), treatment scheme (Control, HFRT, or SDRT), and ordinal time-point (pre-RT, post-RT, or endpoint). LME-estimated normalised regression coefficients, standard errors, and Holm-Bonferonni-adjusted <italic>P</italic>-values were reported for each biomarker. Significance level was set at <italic>α</italic> = 0.05 for all adjusted <italic>P</italic>-values.</p></sec></sec><sec id="S11" sec-type="results"><title>Results</title><sec id="S12"><title>Oestrogen-dependent MCF7 tumours demonstrate greater radiosensivity than triple negative MDA-MB-231 tumours, with improved outcomes using a hypofractionated scheme</title><p id="P20">As would be expected from the more aggressive triple negative breast cancer model, MDA-MB-231 tumours reached the enrolment volume of 400 mm<sup>3</sup> faster than MCF-7 (39.3 ± 6.4 days vs 47.0 ± 8.2 days, <italic>P</italic>= 0.0058, <xref ref-type="fig" rid="F2">Figure 2A,B</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 6</xref>) and when left untreated, showed a greater volume increase from enrolment to endpoint compared to MCF7 xenografts (change in volume, 44.01% ± 13.60% vs. 27.46% ± 9.29%, <italic>P</italic>= 0.0104; <xref ref-type="fig" rid="F2">Figure 2C</xref>). Following RT, all tumours demonstrated growth inhibition compared to controls across models and RT schemes (<italic>P</italic>&lt;0.001 for all). The largest change in tumour volume between enrolment and endpoint was observed in HFRT-treated MCF7 compared to controls (<xref ref-type="fig" rid="F2">Figure 2C</xref>; -13.65% ± 13.15% vs. 27.46% ± 9.29%, <italic>P</italic>&lt; 0.0001), followed by SDRT-treated MCF7 xenografts (3.59% ± 12.27%, <italic>P</italic> = 0.0006), HFRT-treated MDA-MB-231 compared to untreated controls (12.20% ± 6.66% vs. 44.01% ± 13.60%, <italic>P</italic>= 0.00018), and SDRT-treated MDA-MB-231 (9.70% ± 12.97%, <italic>P</italic> = 0.00036). The most responsive groups also displayed decreased proliferation, as shown by Ki67 on IHC, with significantly lower percentage of Ki67 positive nuclei in HFRT-treated MCF7 xenografts compared to controls (<xref ref-type="fig" rid="F2">Figure 2D,E</xref>; 21.98% ± 8.37% vs. 50.04% ± 14.60%, <italic>P</italic>= 0.011), and in the SDRT-treated MCF7 group (23.09% ± 3.08%, <italic>P</italic> = 0.012). Proliferation in MDA-MB-231 tumours was significantly lower only in the HFRT arm (42.45% ± 13.32% vs. 23.95% ± 11.78%, <italic>P</italic>= 0.019). Similarly, DNA damage measured with <italic>γ</italic>-H2AX IHC was significantly increased in all treated groups compared to control mice, across tumour models (<xref ref-type="fig" rid="F2">Figure 2F,G</xref>; <italic>P</italic>&lt;0.01 for all). The measured change in tumour volume was correlated with <italic>ex vivo</italic> IHC markers of response, Ki67 and <italic>γ</italic>-H2AX (<italic>r</italic> = 0.66, <italic>P</italic> = 0.0030; <italic>r</italic> = -0.72, <italic>P</italic> = 0.0008. respectively). Necrotic areas were higher in treated groups than in controls in both models (<italic>P</italic>&lt;0.05, except for SDRT-treated MCF7 vs. MCF7 controls; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 7</xref>). Thus, the oestrogen-dependant MCF7 model was confirmed to be a more radiosensitive breast cancer model than the MDA-MB-231 triple negative breast cancer model. The hypofractionated scheme (HFRT) resulted in improved tumour control in both models, compared to the stereotactic ablative scheme (SDRT), highlighting the benefits of fractionation in RT.</p><p id="P21">To assess the tumour vascular microenvironment in both models, blood vasculature and intratumoural hypoxia were characterised at endpoint on IHC. Double positive CD31-ASMA areas, taken to reflect vascular maturity, were higher in MCF7 than in the MDA-MB-231 tumour sections in the control group (12.39% ± 1.52% vs. 8.46% ± 1.83%, <italic>P</italic>= 0.0014; <xref ref-type="fig" rid="F3">Figure 3A,B</xref>). The HIF1-<italic>α</italic> positive area, taken to reflect hypoxia, was also lower in MCF7 xenografts than in MDA-MB-231, but not significantly (13.13% ± 4.83% vs. 17.28% ± 3.44%, <italic>P</italic>= 0.11; <xref ref-type="fig" rid="F3">Figure 3C,D</xref>). RT-treated tumours displayed significantly less mature vasculature as seen on CD31-ASMA, compared to controls in both models (<italic>P</italic> &lt; 0.01, except HFRT-treated MDA-MB-321 tumours). HIF1-<italic>α</italic> staining was only significantly decreased in SDRT-treated tumour sections compared to controls in both models (MCF7, <italic>P</italic> = 0.047; and MDA-MB-231, <italic>P</italic> = 0.0045). Hence, MCF7 xenografts were confirmed to possess improved vessel coverage and intratumoural oxygenation in comparison to MDA-MB-231 xenografts, and RT was shown to alter the tumour vascular microenvironment, with greater reduction in vessel maturity and HIF1-<italic>α</italic> staining observed in SDRT-treated tumours.</p></sec><sec id="S13"><title>Photoacoustic imaging reveals clear differences in vascular microenvironments at baseline in the two models that correlate with radiotherapy outcomes</title><p id="P22">At enrolment, MCF7 and MDA-MB-231 xenografts were imaged with tomographic PAI 24h pre-RT (<xref ref-type="fig" rid="F4">Figure 4A</xref>). Prior to the administration of any treatment, THb was higher in MCF7 tumours than MDA-MB-231 tumours (0.126 ± 0.026 vs. 0.102 ± 0.020, <italic>P</italic>= 0.0032; <xref ref-type="fig" rid="F4">Figure 4B</xref>) as was sO<sub>2</sub>, although non-significantly (0.408 ± 0.096 vs. 0.362 ± 0.055, <italic>P</italic>= 0.050; <xref ref-type="fig" rid="F4">Figure 4C</xref>), in line with previous findings (<xref ref-type="bibr" rid="R51">51</xref>). Intratumoural distribution of sO<sub>2</sub> displayed less heterogeneity in the MCF7 compared to the MDA-MB-231 model (SD of sO<sub>2</sub> pre-RT, 0.091 ± 0.035 vs. 0.137 ± 0.050, <italic>P</italic>= 0.047; <xref ref-type="fig" rid="F4">Figure 4D</xref>). Upon administration of a change in breathing gas to 100% oxygen, the change in sO<sub>2</sub> and the fraction of pixels responding to gas challenge were both higher in the MCF7 tumours compared to the MDA-MB-231 (ΔsO<sub>2</sub> pre-RT, 0.043 ± 0.014 vs. 0.034 ± 0.013, <italic>P</italic>= 0.039; RF pre-RT, 0.588 ± 0.188 vs. 0.469 ± 0.097, <italic>P</italic>= 0.018 <xref ref-type="fig" rid="F4">Figure 4E,F</xref>) indicating greater vascular maturity.</p><p id="P23">We evaluated correlations across both models between pre-RT PAI biomarkers and endpoint histopathological IHC markers to assess the potential of tomographic PAI to reflect the underlying molecular changes that could predict future RT response. THb and SD of sO<sub>2</sub> at baseline were correlated with the change in tumour volume (<italic>r</italic> = -0.38, <italic>P</italic> = 0.016, and <italic>r</italic> = 0.42, <italic>P</italic> = 0.0041, respectively; <xref ref-type="fig" rid="F4">Figure 4G</xref>). Baseline sO<sub>2</sub> also showed a significant correlation with <italic>γ</italic>-H2AX (<italic>r</italic> = 0.41, <italic>P</italic> = 0.0059; <xref ref-type="fig" rid="F4">Figure 4G</xref>). These findings indicate that increased blood content pre-RT and lower heterogeneity in oxygenation were associated with improved RT efficacy. Higher tissue oxygenation was related to a higher extent of DNA damage, which would be expected given the well-known oxygen enhancement effect. Overall, using tomographic PAI, MDA-MB-231 xenograft tumours displayed higher tissue oxygenation heterogeneity, lower tumour blood content, and weaker intratumoural oxygen diffusion ability than the MCF7 model, which correlated with poorer treatment response at endpoint (<xref ref-type="fig" rid="F4">Figure 4H</xref>).</p><p id="P24">Considering the vascular architecturein more detail, mesoscopic PAI indicated a denser peripheral perfused vasculature in MCF7 xenografts compared to MDA-MB-231 xenografts (vascular density, 236.4 ± 84.5 μm<sup>−3</sup> vs. 153.9 ± 41.2 μm<sup>−3</sup>, <italic>P</italic>= 0.00006; <xref ref-type="fig" rid="F5">Figure 5A,B</xref>). A higher number of vascular connected components were also observed in MCF7 tumours, corresponding to the number of perfused vessel segments connected in the captured vascular skeletons (103.13 ± 57.48 vs. 64.09 ± 20.61, <italic>P</italic> = 0.00185; <xref ref-type="fig" rid="F5">Figure 5C</xref>). Although the density of vascular networks between models was different, the overall vascular morphology (BV, diameters and looping structures, <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 8</xref>) captured close to the tumour surface was not significantly different. The measured pre-RT blood volume (BV) was significantly correlated with biomarkers of RT response at endpoint (change in tumour volume <italic>r</italic> = -0.34, <italic>P</italic> = 0.022, Ki67 <italic>r</italic> = -0.48, <italic>P</italic> = 0.0016, <italic>γ</italic>-H2AX <italic>r</italic> = 0.50, <italic>P</italic> = 0.0017; <xref ref-type="fig" rid="F5">Figure 5D</xref>). Similarly, increased loops normalised to BV was associated with decreased proliferation (Ki67, <italic>r</italic> = -0.49, <italic>P</italic> = 0.0018) and increased DNA damage (<italic>r</italic> = 0.36, <italic>P</italic> = 0.034). Overall, MCF7 xenografts displayed a denser perfused vascular network at tumour periphery compared to that of the MDA-MB-231, and measured BV and looping structures were associated with improved tumour response to RT (<xref ref-type="fig" rid="F5">Figure 5E</xref>).</p></sec><sec id="S14"><title>Longitudinal photoacoustic imaging can predict and detect early tumour response to radiotherapy</title><p id="P25">PAI tomography scans were acquired longitudinally including at 24h post-RT in both treatment arms (<xref ref-type="fig" rid="F6">Figure 6A,B</xref>). On tomographic PAI, the change in THb from baseline across time-points, tumour models and treatment arms was explained with LME modelling. On average, THb increased over time-points, in groups treated with SDRT, and differed between models (time-point normalised regression coefficient [NRC], 0.069 ± 0.026, <italic>P</italic> = 0.009; SDRT arm NRC, 0.159 ± 0.065, <italic>P</italic> = 0.0014; and tumour model NRC, 0.119 ± 0.053, <italic>P</italic> = 0.025, respectively; <xref ref-type="fig" rid="F6">Figure 6C,E</xref>). In fact, when comparing between treatment arms in both tumour models, 24h post-RT THb values normalised to pre-RT scan were greater in SDRT-treated groups compared to controls, although not significantly.</p><p id="P26">LME modelling revealed that sO<sub>2</sub> changed modestly in our dataset, and only significantly from baseline between the different tumour models (tumour model NRC, 0.071 ± 0.036, <italic>P</italic> = 0.046; <xref ref-type="fig" rid="F6">Figure 6D,F</xref>). No significant sO<sub>2</sub> changes were measured 24h post-RT. Nonetheless, sO<sub>2</sub> quantified on the 24h post-RT scans was indicative of treatment response across groups when conducting bivariate correlation analysis with endpoint IHC markers (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 9</xref>). sO<sub>2</sub> at 24h post-RT also showed strong correlation with change in tumour volume, proliferation, and DNA damage (change in tumour volume, <italic>r</italic> = -0.47, <italic>P</italic> = 0.014; Ki67, <italic>r</italic> = -0.55, <italic>P</italic> = 0.0053; and <italic>γ</italic>-H2AX, <italic>r</italic> = 0.54, <italic>P</italic> = 0.0051). Moreover, mean sO<sub>2</sub> negatively correlated with endpoint hypoxia (HIF1-<italic>α</italic>, <italic>r</italic> = -0.42, <italic>P</italic> = 0.0188), while its SD was also predictive of endpoint decrease in tumour size (<italic>r</italic> = 0.46, <italic>P</italic> = 0.034). SD of sO<sub>2</sub> can be appreciated in the sO<sub>2</sub> density distribution subplots of <xref ref-type="fig" rid="F6">Figure 6A,B</xref>. Thus, PAI tomography could capture early increases in intratumoural blood content, which are likely related to radiation-induced transient inflammatory activity following high doses of radiation, and longitudinal oxygenation mapping was found to be indicative of endpoint tumour control.</p><p id="P27">On mesoscopic PAI, blood volume decreased most in SDRT-treated mice, then in HFRT-treated groups, and was altered with increasing time-points according to LME analysis (SDRT arm NRC, -0.500 ± 0.144, <italic>P</italic> = 0.001; HFRT arm NRC, -0.405 ± 0.150, <italic>P</italic> = 0.007; and time-points NRC, 0.111 ± 0.055, <italic>P</italic> = 0.045; <xref ref-type="fig" rid="F7">Figure 7A,B</xref>). Similarly, vascular density and connected components changed most over time, as shown by LME modelling (time-points NRC, 0.082 ± 0.034, <italic>P</italic> = 0.015; 0.188 ± 0.050, <italic>P</italic> = 0.0002; SDRT arm NRC, -0.373 ± 0.143, <italic>P</italic> = 0.009; and HFRT arm NRC, -0.326 ± 0.149, <italic>P</italic> = 0.029). Normalised looping structures were decreased in both treatment groups and changed with time-points (HFRT arm NRC, -0.384 ± 0.152, <italic>P</italic> = 0.012; SDRT arm NRC, -0.373 ± 0.146, <italic>P</italic> = 0.011; and time-point NRC, 0.134 ± 0.054, <italic>P</italic> = 0.014). Average diameters extracted from longitudinal mesoscopic PAI did not reveal any difference between models, treatments or time-points.</p><p id="P28">Blood volume was decreased in the MCF7 xenograft model within 24h post-RT in SDRT-treated mice, before any change in tumour size was observed (normalised BV, <italic>P</italic> = 0.020; <xref ref-type="fig" rid="F7">Figure 7A</xref>), but not in MDA-MB-231 (<xref ref-type="fig" rid="F7">Figure 7B</xref>). At this early time-point, the vascular density was also decreased in both models in treated groups, but not significantly (<xref ref-type="fig" rid="F7">Figure 7C,D</xref>). In the more radiosensitive MCF7 model, the number of looping structures was significantly decreased compared to control in SDRT-treated mice (<italic>P</italic> = 0.029; <xref ref-type="fig" rid="F7">Figure 7E</xref>), thus decreasing the overall tortuosity of the vascular network, which was not observed in the more radioresistant MDA-MB-231 xenografts (<xref ref-type="fig" rid="F7">Figure 7F</xref>). The observation of significant BV differences only in MCF7 tumours treated with ablative doses of radiation likely indicates endothelial cell damage at high doses. Finally, the measured BV 24h post-RT was predictive of Ki67 positive areas at endpoint (<italic>r</italic> = 0.32, <italic>P</italic> = 0.0384; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 9</xref>), and BV and loops (normalised to BV) were both correlated with hypoxia (HIF1-<italic>α</italic>, <italic>r</italic> = -0.34, <italic>P</italic> = 0.0487; and <italic>r</italic> = -0.58, <italic>P</italic> = 0.00013; respectively). Thus, PAI mesoscopy provided early detection of response in the tumour vasculature, prior to any change in tumour size, indicating its sensitivity to radiation-induced vessel pruning in the radiosensitive model.</p></sec><sec id="S15"><title>Differential vascular response to radiation therapy schemes revealed by photoacoustic imaging at endpoint</title><p id="P29">At endpoint, seven days on average following the last day of treatment, growth was significantly delayed in treated groups of both investigated breast cancer models (<xref ref-type="fig" rid="F2">Figure 2</xref>). A final imaging session was conducted prior to tumour excision for <italic>ex vivo</italic> analysis. THb increased between pre-RT and endpoint in SDRT-treated MCF7 and MDA-MB-231 xenografts compared to their respective controls, and while the opposite trend was observed with HFRT-treated groups (<xref ref-type="fig" rid="F6">Figure 6C,D</xref>), neither reached statistical significance. sO<sub>2</sub> was higher in treated MCF7 tumours compared to controls, but only significantly in HFRT-treated mice (<italic>P</italic>= 0.017), while no significant difference was observed in the more radioresistant MDA-MB-231 model. In terms of imaging-IHC correlations, THb was negatively correlated with hypoxia (HIF1-<italic>α</italic>, <italic>r</italic> = -0.45, <italic>P</italic> = 0.038).</p><p id="P30">On mesoscopic PAI, the change in BV from baseline was significantly lower in MCF7 tumour-bearing treated groups compared to controls (HFRT, <italic>P</italic> = 0.028; and SDRT, <italic>P</italic> = 0.017; <xref ref-type="fig" rid="F7">Figure 7A</xref>), and was also lower in treated MDA-MB-231 xenografts but not significantly (HFRT, <italic>P</italic> = 0.35; and SDRT, <italic>P</italic> = 0.082; <xref ref-type="fig" rid="F7">Figure 7B</xref>). The same trend was observed in measured blood vessel density in both MCF7 and MDA-MB-231 xenografts, but was not significant. The normalised count of looping structures was significantly reduced at endpoint in treated MCF7 tumours only (HFRT, <italic>P</italic> = 0.0079; SDRT, <italic>P</italic> = 0.014). Interestingly, the group averages of total BV change from baseline decreased in the same fashion as the CD31-ASMA percent area in both models, with higher quantified values in control, HFRT and then SDRT (<xref ref-type="fig" rid="F3">Figure 3A,B</xref>). BV was also negatively correlated with the change in tumour size (<italic>r</italic> = 0.53, <italic>P</italic> = 0.0042; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 9</xref>). CC and density at endpoint were both positively correlated with proliferation assessed on Ki67 IHC (<italic>r</italic> = 0.48, <italic>P</italic> = 0.0052; and <italic>r</italic> = 0.42, <italic>P</italic> = 0.023; respectively) and CC were also negatively correlated with the extent of DNA damage (<italic>r</italic> = -0.42, <italic>P</italic> = 0.035). Taken together, our findings indicate a higher volume of denser functional blood vessels at endpoint is correlated with poorer overall tumour response, or radioresistance, in the investigated breast cancer models.</p></sec></sec><sec id="S16" sec-type="discussion"><title>Discussion</title><p id="P31">The challenge of treating hypoxic solid tumours with radiotherapy has long been recognised, yet is rarely acted upon in treatment practice. With the increasing use of hypofractionation, hypoxia becomes a more critical consideration and there is a clear need to develop suitable imaging biomarkers to detect and monitor changes in tumour vascular architecture and function in response to RT treatment. In this study, following implementation of dosimetric quality assurance protocols (<xref ref-type="bibr" rid="R74">74</xref>), we sought to demonstrate the potential of PAI in this context, comparing hypofractionated and ablative single dose RT schemes in breast cancer xenografts exhibiting differential radiation responses showing wide-ranging potential for PAI guidance of RT (<xref ref-type="fig" rid="F8">Figure 8</xref>).</p><p id="P32"><italic>Ex vivo</italic> analysis of the two models aligned with the literature, showing MCF-7 tumours to have a more developed and mature vasculature, associated with lower hypoxia (<xref ref-type="bibr" rid="R51">51</xref>, <xref ref-type="bibr" rid="R75">75</xref>) and radiosensitivity (<xref ref-type="bibr" rid="R47">47</xref>–<xref ref-type="bibr" rid="R50">50</xref>, <xref ref-type="bibr" rid="R76">76</xref>). Both models showed gradual reductions in vessel maturity from control, to HFRT and then SDRT arms, alongside a characteristic decrease in hypoxia through HIF1-<italic>α</italic> IHC in SDRT-treated groups.</p><p id="P33"><italic>In vivo</italic> imaging biomarkers evaluated in this study revealed pre-RT differences between the MCF7 and MDA-MB-231 models in terms of tumour blood content, oxygenation, tissue oxygen diffusion, and vascular morphology, aligned with prior work (<xref ref-type="bibr" rid="R51">51</xref>). We found that increased THb and decreased heterogeneity of oxygen saturation (SD of sO<sub>2</sub>) prior to treatment were associated with tumour control at endpoint across both models. It is worth noting that although MDA-MB-231 have been reported to have a higher microvascular density than MCF7 on IHC (<xref ref-type="bibr" rid="R51">51</xref>, <xref ref-type="bibr" rid="R75">75</xref>), the mesoscopic PAI measurements demonstrated a significantly denser network in the MCF7 model, even though the total blood volume did not differ. This discrepancy could be explained by the fact that mesoscopic PAI depicts only the blood-filled vessels larger than its in-plane resolution (≈ 20 μm) at the peripheral rim of the tumour, whereas IHC analyses the core and samples all vessels expressing endothelial cell proteins. Of note, a previous study has shown that orthotopic breast cancer tumours used in our study produce more vascularised tumours compared to subcutaneous tumours, used in prior studies (<xref ref-type="bibr" rid="R77">77</xref>). Encouragingly though, increased blood volume pre-RT in mesoscopic PAI correlated with endpoint response, similar to whole tumour-evaluated THb on tomographic PAI.</p><p id="P34">Others have reported tumour blood oxygen saturation (sO<sub>2</sub>) pre-treatment as a predictive biomarker for RT response in patient-derived xenografts of head &amp; neck cancer or pancreatic cancer models (<xref ref-type="bibr" rid="R44">44</xref>, <xref ref-type="bibr" rid="R78">78</xref>, <xref ref-type="bibr" rid="R79">79</xref>). However, even though sO<sub>2</sub> was higher on average in the more radiosensitive MCF7 at baseline, we did not observe a significant difference in our study; sO<sub>2</sub> was only significantly different at endpoint. Most interestingly, we were able to assess <italic>in vivo</italic> the well-known oxygen-enhancement effect in RT (<xref ref-type="bibr" rid="R10">10</xref>), by finding pre-RT a correlation between sO<sub>2</sub> as measured with PAI tomography and the extent of DNA damage at endpoint, which was consistent across models and treatment groups at the individual level. Our results confirm those of a previous study using nanosonophores as a PAI contrast agent for oxygen sensing, which also showed that pre-RT oxygen distribution was associated with post-RT DNA damage <italic>ex vivo</italic> on <italic>γ</italic>-H2AX in breast cancer patient-derived xenografts (<xref ref-type="bibr" rid="R80">80</xref>).</p><p id="P35">Change in blood oxygen saturation and the responding fraction under gas challenge pre-RT were were both significantly higher at baseline in the MCF7 groups than in the MDA-MB-231, indicating better intratumoural oxygen diffusion, linked to higher radiosensitivity in MCF7. A prior study investigating the same models revealed that blood oxygen level dependent-MRI ΔR2*, a surrogate marker for oxygen delivery under gas challenge, showed improved blood oxygen diffusion in MCF7 compared to MDA-MB-231 xenografts, in-line with our findings (<xref ref-type="bibr" rid="R75">75</xref>). Increased tumour ΔsO<sub>2</sub> pre-treatment was also demonstrated to be a predictive biomarker in pancreatic cancer models (<xref ref-type="bibr" rid="R79">79</xref>, <xref ref-type="bibr" rid="R81">81</xref>), highlighting the potential of using a breathing gas challenge to extract predictive PAI biomarkers.</p><p id="P36">Importantly, PAI revealed the differential effect of ablative (SDRT) and hypofractionated (HFRT) courses of RT in the two models. Since RT has the potential to stimulate tumoural neovascularisation and perfusion through an acute inflammatory response (<xref ref-type="bibr" rid="R82">82</xref>), and RT can also prune hypoperfused vessels (<xref ref-type="bibr" rid="R71">71</xref>, <xref ref-type="bibr" rid="R83">83</xref>–<xref ref-type="bibr" rid="R85">85</xref>), blood flow to the tumour may be transiently increased following a dose of RT, thereby increasing THb. Just 24h after radiation delivery, an increase in tumour blood content was observed in SDRT-treated mice, indicating a direct vascular contribution to radiation response. We also confirmed that vessel loops decrease significantly at both 24h after treatment and at endpoint, demonstrating vessel pruning. Considering oxygenation response, we that higher sO<sub>2</sub> 24h post-RT was highly correlated with endpoint tumour control across groups and sO 2 was significantly increased at endpoint in the more responsive MCF7 tumours. Increased sO<sub>2</sub> post-SDRT has also been observed by others (<xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R86">86</xref>, <xref ref-type="bibr" rid="R87">87</xref>). Overall, improvement in oxygenation can likely be attributed to the reduced oxygen consumption of damaged tumour cells, indicative of response, rather than to an increase in oxygen supply or oxygen diffusion.</p><p id="P37">Despite these promising findings, there are limitations to our study. A first key limitation is that the imaging modalities investigated here only provide surrogate biomarkers of complex biological processes focusing on tissue vascularisation, blood content and oxygenation – and not cell death – and must therefore be carefully interpreted. For instance, tomographic PAI-derived blood oxygen saturation is not an absolute oxygenation measurement, but provides insightful relative sampling of the intratumoural oxy-and deoxyhaemoglobin with high technical reproducibility (&lt; 4% variability) (<xref ref-type="bibr" rid="R88">88</xref>, <xref ref-type="bibr" rid="R89">89</xref>). Similarly, mesoscopic PAI enables only the characterisation of superficial (<italic>approx</italic> 4 mm) perfused vasculature <italic>in vivo</italic>. The full extent of the investigated tumour vascular networks – especially in perfusion-limited vessels – is not fully captured in this detection configuration. For instance, due to the top illumination and planar detection geometry, vessels approaching 90° to the detection plane are not detected, creating discontinuities in the network and artificially increasing the number of CC (<xref ref-type="bibr" rid="R90">90</xref>). Thus, the quantitative biomarkers presented in this study cannot be taken outside their context or as absolute measurements. Tailored contrast agents that have been introduced recently could be employed for identifying specifically cellular response mechanisms such as senescence (<xref ref-type="bibr" rid="R91">91</xref>, <xref ref-type="bibr" rid="R92">92</xref>).</p><p id="P38">A second key limitation is that we have not completed serial culling of animals to obtain tumour samples at all imaging time-points of interest. Instead, we favoured having paired longitudinal imaging data to improve statistical power, thus decreasing the need for high animal numbers per group. Such <italic>ex vivo</italic> IHC analysis would have provided time-resolved validation of our <italic>in vivo</italic> imaging. Furthermore, we did not keep animals alive longer than 7 days post-RT on average to further monitor tumour growth, vascular alterations, or survival. Thus, considering the time-scale of tumour and vascular response to RT, our imaging-based investigation depicts the earlier phase of response that may not recapitulate the full story, especially in terms of recurrence or revascularisation post-RT (<xref ref-type="bibr" rid="R93">93</xref>). Nevertheless, targeted neoadjuvant RT did improve resectability at endpoint given the decrease in tumour size.</p><p id="P39">Finally, the imaging time-points in terms of days between treated groups were different due to the nature of the hypofractionated (HFRT) vs. single-dose (SDRT) courses of treatment. Even though treatment arms are compared directly, they are only comparable in terms of total dose delivered but not in absolute number of days. Further study would be required to control for the time effect more directly. We believe that changes in intratumoural blood oxygen saturation following RT have an important dose-and time-dependence, which could be tumour-specific, as highlighted in our comparisons with prior literature. We acknowledge that there is a time compartment to radiation response, but report here differences related to the impact of fractionation and dose per fraction.</p><p id="P40">In terms of clinical translatability, although neoadjuvant RT is not the main line of treatment in breast cancer patients, it has been shown to be beneficial in low-risk or early-stage breast cancer, including for ER+ cases with potential chemo-resistance (<xref ref-type="bibr" rid="R94">94</xref>–<xref ref-type="bibr" rid="R96">96</xref>). Indeed, there has been an increasing interest in breast cancer pre-operative hypofractionated RT or even SDRT, enabled by the increased precision in tumour targeting provided by recent developments in integrated imaging and accelerator technologies (<italic>e.g.</italic> magnetic resonance-guided RT, PET-guided – also termed biology-guided – RT, or camera-guided CyberKnife) that decrease overall treatment time (<xref ref-type="bibr" rid="R97">97</xref>). Pre-operative partial breast irradiation using 20 Gy SDRT to the tumour volume, similar to that described in our preclinical study, has been investigated and shown oncologically safe in a feasibility study and a 5-year follow-up study (<xref ref-type="bibr" rid="R61">61</xref>, <xref ref-type="bibr" rid="R62">62</xref>), and in another trial using 21 Gy SDRT (<xref ref-type="bibr" rid="R63">63</xref>), and are both being further investigated in on-going clinical trials (ClinicalTrials.gov ID, NCT03863301, NCT02212860, and NCT04679454; Australian New Zealand Clinical Trials Registry, ACTRN12621000659808) (<xref ref-type="bibr" rid="R64">64</xref>, <xref ref-type="bibr" rid="R65">65</xref>). The potential of PAI in this context is multi-faceted, and clinical studies should investigate the use of quantitative PAI in breast cancer patients receiving RT or combination therapies (<xref ref-type="bibr" rid="R38">38</xref>). For instance, preclinical data in numerous cancer models already support the benefits of using functional imaging modalities to guide the boosting of the radiation dose to tumour hypoxic fraction, using oxygen-guided spatially modulated dose delivery (<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R98">98</xref>). Thus, the role of label-free portable bedside clinical photoacoustic imagers in the radiation oncology clinics should be further investigated, especially in the context of treatment adaptation.</p></sec><sec id="S17" sec-type="conclusions"><title>Conclusion</title><p id="P41">We demonstrated that PAI reveals the differential effect between hypofractionated and ablative courses of RT in two breast cancer models, with increased blood content and gas challenge response pre-RT associated with improved treatment outcomes. We showed that PAI could capture early RT response, days before any change in tumour volume was measured, informing on radioresistance. The vascular alterations resulting from ablative doses of radiation were seen within 24h of treatment in the more radiosensitive model. Hence, the molecular contrast provided by PAI shows promise for measuring functional response and shedding new light on the vascular compartment of radiation response, as well as the impact of hypoxia on radioresistance <italic>in vivo</italic>. We envision that PAI biomarkers will benefit other cancer types treated with RT, such as already demonstrated preclinically in head &amp; neck cancer (<xref ref-type="bibr" rid="R44">44</xref>, <xref ref-type="bibr" rid="R45">45</xref>), with high translational potential in those more superficial tumour sites. Visualising and quantifying the tumour vascular phenotype <italic>in vivo</italic> thus has the potential to enable personalised RT through biology-tailored targeting and further inform the course of treatment.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Materials</label><media xlink:href="EMS206122-supplement-Supplementary_Materials.pdf" mimetype="application" mime-subtype="pdf" id="d83aAcFbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S18"><title>Acknowledgements</title><p>TLL, MEO, EVB, TRE, LW, MAG, LH, CB, PWS, and SEB acknowledge the support from Cancer Research UK (CRUK) under grant numbers C14303/A17197, C9545/A29580, C47594/A16267, C197/A16465, C47594/A29448, and CRUK RadNet Cambridge under the grant number C17918/A28870. SEB also receives funding support from the UKRI Engineering and Physical Sciences Research Council (EP/R003599/1, EP/X037770/1 and EP/V027069/1). TLL is supported by the Cambridge Trust. EVB is supported by CRUK RadNet. LH acknowledges research support from Against Breast Cancer. We thank the CRUK Cambridge Institute’s Biological Resources Unit, Imaging Core, Histopathological Core, Light Microscopy, Research Instrumentation and Cell Services, and the RadNet Small Animal Hospital for their support in conducting this research. We also acknowledge the CRUK RadNet leadership team, Prof. Charlotte Coles and Nicola Leblond, for infrastructure support. We would like to thank Prof. Raj Jena and Dr. Florian Markowetz for useful discussions and guidance throughout study conduction.</p></ack><sec id="S19" sec-type="data-availability"><title>Data availability</title><p id="P42">All code and data associated with the results presented in this manuscript will be made available upon acceptance of the article at: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.17863/CAM.118247">https://doi.org/10.17863/CAM.118247</ext-link></p></sec><fn-group><fn id="FN1" fn-type="con"><p id="P43"><bold>Author contributions</bold></p><p id="P44">TLL: conceptualisation, data curation, formal analysis, funding acquisition, investigation, methodology, software, validation, visualisation, writing - original draft. M-EO: investigation, methodology, project administration, supervision, validation, writing - review &amp; editing. EVB: investigation, methodology, validation, writing - review &amp; editing. TRE: methodology, software, validation, writing - review &amp; editing. LW: investigation, validation, writing - review &amp; editing. MAG: investigation, writing - review &amp; editing. LH: investigation, validation, writing - review &amp; editing. CB: formal analysis, investigation, methodology, software, writing - review &amp; editing. SK: investigation, methodology, writing - review &amp; editing. YC: investigation, methodology, writing - review &amp; editing. LY: investigation, methodology, resources, project administration, writing - review &amp; editing. PWS: formal analysis, investigation, methodology, software, supervision, validation, visualisation, writing - review &amp; editing. SEB: conceptualisation, funding acquisition, methodology, project administration, resources, supervision, validation, writing - review &amp; editing.</p></fn><fn id="FN2" fn-type="conflict"><p id="P45"><bold>Competing Financial Interests</bold></p><p id="P46">The authors have no conflict of interest related to the present manuscript to disclose.</p></fn></fn-group><ref-list><title>Bibliography</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewhirst</surname><given-names>Mark W</given-names></name><name><surname>Cao</surname><given-names>Yiting</given-names></name><name><surname>Moeller</surname><given-names>Benjamin</given-names></name></person-group><article-title>Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response</article-title><source>Nature Reviews Cancer</source><year>2008</year><volume>8</volume><issue>6</issue><fpage>425</fpage><lpage>437</lpage><pub-id pub-id-type="pmcid">PMC3943205</pub-id><pub-id pub-id-type="pmid">18500244</pub-id><pub-id pub-id-type="doi">10.1038/nrc2397</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begg</surname><given-names>Katheryn</given-names></name><name><surname>Tavassoli</surname><given-names>Mahvash</given-names></name></person-group><article-title>Inside the hypoxic tumour: reprogramming of the ddr and radioresistance</article-title><source>Cell Death Discovery</source><year>2020</year><volume>6</volume><issue>1</issue><fpage>77</fpage><pub-id pub-id-type="pmcid">PMC7434912</pub-id><pub-id pub-id-type="pmid">32864165</pub-id><pub-id pub-id-type="doi">10.1038/s41420-020-00311-0</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horsman</surname><given-names>MR</given-names></name><name><surname>Overgaard</surname><given-names>J</given-names></name></person-group><article-title>The impact of hypoxia and its modification of the outcome of radiotherapy</article-title><source>J Radiat Res</source><year>2016</year><volume>57</volume><issue>Suppl 1</issue><fpage>i90</fpage><lpage>i98</lpage><pub-id pub-id-type="pmcid">PMC4990104</pub-id><pub-id pub-id-type="pmid">26983987</pub-id><pub-id pub-id-type="doi">10.1093/jrr/rrw007</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><article-title>The hypoxic tumor microenvironment: A driving force for breast cancer progression</article-title><source>Biochim Biophys Acta</source><year>2016</year><volume>1863</volume><issue>3</issue><fpage>382</fpage><lpage>391</lpage><pub-id pub-id-type="pmcid">PMC4678039</pub-id><pub-id pub-id-type="pmid">26079100</pub-id><pub-id pub-id-type="doi">10.1016/j.bbamcr.2015.05.036</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sousa</surname><given-names>Claudia</given-names></name><name><surname>Cruz</surname><given-names>Mafalda</given-names></name><name><surname>Neto</surname><given-names>Ana</given-names></name><name><surname>Pereira</surname><given-names>Kayla</given-names></name><name><surname>Peixoto</surname><given-names>Marta</given-names></name><name><surname>Bastos</surname><given-names>Joana</given-names></name><name><surname>Henriques</surname><given-names>Monica</given-names></name><name><surname>Roda</surname><given-names>Domingos</given-names></name><name><surname>Marques</surname><given-names>Rui</given-names></name><name><surname>Miranda</surname><given-names>Cristina</given-names></name><name><surname>Melo</surname><given-names>Gilberto</given-names></name><etal/></person-group><article-title>Neoadjuvant radiotherapy in the approach of locally advanced breast cancer</article-title><source>ESMO Open</source><year>2020</year><volume>5</volume><issue>2</issue><elocation-id>e000640</elocation-id><pub-id pub-id-type="pmcid">PMC7082639</pub-id><pub-id pub-id-type="pmid">32152044</pub-id><pub-id pub-id-type="doi">10.1136/esmoopen-2019-000640</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maire</surname><given-names>Mathilde</given-names></name><name><surname>Debled</surname><given-names>Marc</given-names></name><name><surname>Petit</surname><given-names>Adeline</given-names></name><name><surname>Fournier</surname><given-names>Marion</given-names></name><name><surname>Macgrogan</surname><given-names>Gaetan</given-names></name><name><surname>Quenel-Thueux</surname><given-names>Nathalie</given-names></name><name><surname>Charitansky</surname><given-names>Helene</given-names></name><name><surname>Mathoulin-Pelissier</surname><given-names>Simone</given-names></name><name><surname>Bonnefoi</surname><given-names>Herve</given-names></name><name><surname>de Lara</surname><given-names>Christine Tunon</given-names></name></person-group><article-title>Neoadjuvant chemotherapy and radiotherapy for locally advanced breast cancer: Safety and efficacy of reverse sequence compared to standard technique?</article-title><source>European Journal of Surgical Oncology</source><year>2022</year><volume>48</volume><issue>8</issue><fpage>1699</fpage><lpage>1705</lpage><pub-id pub-id-type="pmid">35523623</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chidley</surname><given-names>Phoebe</given-names></name><name><surname>Foroudi</surname><given-names>Farshad</given-names></name><name><surname>Tacey</surname><given-names>Mark</given-names></name><name><surname>Khor</surname><given-names>Richard</given-names></name><name><surname>Yeh</surname><given-names>Janice</given-names></name><name><surname>Bevington</surname><given-names>Elaine</given-names></name><name><surname>Hyett</surname><given-names>Anthony</given-names></name><name><surname>Loh</surname><given-names>Su Wen</given-names></name><name><surname>Chew</surname><given-names>Grace</given-names></name><name><surname>McCracken</surname><given-names>James</given-names></name><name><surname>Neoh</surname><given-names>Derek</given-names></name><etal/></person-group><article-title>Neoadjuvant radiotherapy for locally advanced and high-risk breast cancer</article-title><source>Journal of Medical Imaging and Radiation Oncology</source><year>2021</year><volume>65</volume><issue>3</issue><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">33821576</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Yuan-Hong</given-names></name><name><surname>Chidley</surname><given-names>Phoebe</given-names></name><name><surname>Admojo</surname><given-names>Lorenztino</given-names></name><name><surname>Jassal</surname><given-names>Sunil</given-names></name><name><surname>Zantuck</surname><given-names>Natalie</given-names></name><name><surname>Foroudi</surname><given-names>Farshad</given-names></name><name><surname>Bevington</surname><given-names>Elaine</given-names></name><name><surname>Chew</surname><given-names>Grace</given-names></name><name><surname>Hyett</surname><given-names>Anthony</given-names></name><name><surname>Loh</surname><given-names>Su Wen</given-names></name><name><surname>Li Ng</surname><given-names>Suat</given-names></name><etal/></person-group><article-title>Pathologic complete response and oncologic outcomes in locally advanced breast cancers treated with neoadjuvant radiation therapy: An australian perspective</article-title><source>Practical Radiation Oncology</source><year>2023</year><volume>13</volume><issue>4</issue><fpage>301</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">36599393</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomlinson</surname><given-names>RH</given-names></name><name><surname>Gray</surname><given-names>LH</given-names></name></person-group><article-title>The histological structure of some human lung cancers and the possible implications for radiotherapy</article-title><source>British Journal of Cancer</source><year>1955</year><volume>9</volume><issue>4</issue><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="pmcid">PMC2073776</pub-id><pub-id pub-id-type="pmid">13304213</pub-id><pub-id pub-id-type="doi">10.1038/bjc.1955.55</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimes</surname><given-names>DR</given-names></name><name><surname>Partridge</surname><given-names>M</given-names></name></person-group><article-title>A mechanistic investigation of the oxygen fixation hypothesis and oxygen enhancement ratio</article-title><source>Biomed Phys Eng Express</source><year>2015</year><volume>1</volume><issue>4</issue><elocation-id>045209</elocation-id><pub-id pub-id-type="pmcid">PMC4765087</pub-id><pub-id pub-id-type="pmid">26925254</pub-id><pub-id pub-id-type="doi">10.1088/2057-1976/1/4/045209</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>RA</given-names></name><name><surname>Keane</surname><given-names>FK</given-names></name><name><surname>Voncken</surname><given-names>FEM</given-names></name><name><surname>Thomas</surname><given-names>CR</given-names><suffix>Jr</suffix></name></person-group><article-title>Contemporary radiotherapy: present and future</article-title><source>Lancet</source><year>2021</year><volume>398</volume><issue>10295</issue><fpage>171</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">34166607</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Diehn</surname><given-names>M</given-names></name><name><surname>Loo</surname><given-names>BW</given-names><suffix>Jr</suffix></name></person-group><article-title>Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2010</year><volume>78</volume><issue>2</issue><fpage>323</fpage><lpage>7</lpage><pub-id pub-id-type="pmcid">PMC2939040</pub-id><pub-id pub-id-type="pmid">20832663</pub-id><pub-id pub-id-type="doi">10.1016/j.ijrobp.2010.04.070</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Carlson</surname><given-names>DJ</given-names></name><name><surname>Brenner</surname><given-names>DJ</given-names></name></person-group><article-title>The tumor radiobiology of srs and sbrt: are more than the 5 rs involved?</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2014</year><volume>88</volume><issue>2</issue><fpage>254</fpage><lpage>62</lpage><pub-id pub-id-type="pmcid">PMC3893711</pub-id><pub-id pub-id-type="pmid">24411596</pub-id><pub-id pub-id-type="doi">10.1016/j.ijrobp.2013.07.022</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epel</surname><given-names>B</given-names></name><name><surname>Maggio</surname><given-names>MC</given-names></name><name><surname>Barth</surname><given-names>ED</given-names></name><name><surname>Miller</surname><given-names>RC</given-names></name><name><surname>Pelizzari</surname><given-names>CA</given-names></name><name><surname>Krzykawska-Serda</surname><given-names>M</given-names></name><name><surname>Sundramoorthy</surname><given-names>SV</given-names></name><name><surname>Aydogan</surname><given-names>B</given-names></name><name><surname>Weichselbaum</surname><given-names>RR</given-names></name><name><surname>Tormyshev</surname><given-names>VM</given-names></name><name><surname>Halpern</surname><given-names>HJ</given-names></name></person-group><article-title>Oxygen-guided radiation therapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2019</year><volume>103</volume><issue>4</issue><fpage>977</fpage><lpage>984</lpage><pub-id pub-id-type="pmcid">PMC6478443</pub-id><pub-id pub-id-type="pmid">30414912</pub-id><pub-id pub-id-type="doi">10.1016/j.ijrobp.2018.10.041</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuks</surname><given-names>Z</given-names></name><name><surname>Kolesnick</surname><given-names>R</given-names></name></person-group><article-title>Engaging the vascular component of the tumor response</article-title><source>Cancer Cell</source><year>2005</year><volume>8</volume><issue>2</issue><fpage>89</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">16098459</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Griffin</surname><given-names>RJ</given-names></name><name><surname>Hui</surname><given-names>S</given-names></name><name><surname>Levitt</surname><given-names>SH</given-names></name><name><surname>Song</surname><given-names>CW</given-names></name></person-group><article-title>Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (sbrt and srs)</article-title><source>Radiat Res</source><year>2012</year><volume>177</volume><issue>3</issue><fpage>311</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">22229487</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>CW</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Griffin</surname><given-names>RJ</given-names></name><name><surname>Park</surname><given-names>I</given-names></name><name><surname>Koonce</surname><given-names>NA</given-names></name><name><surname>Hui</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Dusenbery</surname><given-names>KE</given-names></name><name><surname>Sperduto</surname><given-names>PW</given-names></name><name><surname>Cho</surname><given-names>LC</given-names></name></person-group><article-title>Indirect tumor cell death after high-dose hypofractionated irradiation: Implications for stereotactic body radiation therapy and stereotactic radiation surgery</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2015</year><volume>93</volume><issue>1</issue><pub-id pub-id-type="pmcid">PMC4729457</pub-id><pub-id pub-id-type="pmid">26279032</pub-id><pub-id pub-id-type="doi">10.1016/j.ijrobp.2015.05.016</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>D</given-names></name></person-group><article-title>The tumor vascular endothelium as decision maker in cancer therapy</article-title><source>Front Oncol</source><year>2018</year><volume>8</volume><fpage>367</fpage><pub-id pub-id-type="pmcid">PMC6139307</pub-id><pub-id pub-id-type="pmid">30250827</pub-id><pub-id pub-id-type="doi">10.3389/fonc.2018.00367</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolesnick</surname><given-names>R</given-names></name><name><surname>Fuks</surname><given-names>Z</given-names></name></person-group><article-title>Radiation and ceramide-induced apoptosis</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><issue>37</issue><fpage>5897</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">12947396</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Barros</surname><given-names>M</given-names></name><name><surname>Paris</surname><given-names>F</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C</given-names></name><name><surname>Lyden</surname><given-names>D</given-names></name><name><surname>Rafii</surname><given-names>S</given-names></name><name><surname>Haimovitz-Friedman</surname><given-names>A</given-names></name><name><surname>Fuks</surname><given-names>Z</given-names></name><name><surname>Kolesnick</surname><given-names>R</given-names></name></person-group><article-title>Tumor response to radiotherapy regulated by endothelial cell apoptosis</article-title><source>Science</source><year>2003</year><volume>300</volume><issue>5622</issue><fpage>1155</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12750523</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jared Weinfurtner</surname><given-names>R</given-names></name><name><surname>Raghunand</surname><given-names>Natarajan</given-names></name><name><surname>Stringfield</surname><given-names>Olya</given-names></name><name><surname>Abdalah</surname><given-names>Mahmoud</given-names></name><name><surname>Niell</surname><given-names>Bethany L</given-names></name><name><surname>Ataya</surname><given-names>Dana</given-names></name><name><surname>Williams</surname><given-names>Angela</given-names></name><name><surname>Mooney</surname><given-names>Blaise</given-names></name><name><surname>Rosa</surname><given-names>Marilin</given-names></name><name><surname>Lee</surname><given-names>Marie C</given-names></name><name><surname>Khakpour</surname><given-names>Nazanin</given-names></name><etal/></person-group><article-title>Mri response to pre-operative stereotactic ablative body radiotherapy (sabr) in early stage er/pr+ her2-breast cancer correlates with surgical pathology tumor bed cellularity</article-title><source>Clinical Breast Cancer</source><year>2022</year><volume>22</volume><issue>2</issue><fpage>e214</fpage><lpage>e223</lpage><pub-id pub-id-type="pmid">34384695</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qadir</surname><given-names>Ayyaz</given-names></name><name><surname>Singh</surname><given-names>Nabita</given-names></name><name><surname>Moe</surname><given-names>Aung Aung Kywe</given-names></name><name><surname>Cahoon</surname><given-names>Glenn</given-names></name><name><surname>Lye</surname><given-names>Jessica</given-names></name><name><surname>Chao</surname><given-names>Michael</given-names></name><name><surname>Foroudi</surname><given-names>Farshad</given-names></name><name><surname>Uribe</surname><given-names>Sergio</given-names></name></person-group><article-title>Potential of mri in assessing treatment response after neoadjuvant radiation therapy treatment in breast cancer patients: A scoping review</article-title><source>Clinical Breast Cancer</source><year>2024</year><pub-id pub-id-type="pmid">38906720</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimes</surname><given-names>DR</given-names></name><name><surname>Warren</surname><given-names>DR</given-names></name><name><surname>Warren</surname><given-names>S</given-names></name></person-group><article-title>Hypoxia imaging and radiotherapy: bridging the resolution gap</article-title><source>Br J Radiol</source><year>2017</year><volume>90</volume><issue>1076</issue><elocation-id>20160939</elocation-id><pub-id pub-id-type="pmcid">PMC5603947</pub-id><pub-id pub-id-type="pmid">28540739</pub-id><pub-id pub-id-type="doi">10.1259/bjr.20160939</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Alonzo</surname><given-names>RA</given-names></name><name><surname>Gill</surname><given-names>S</given-names></name><name><surname>Rowshanfarzad</surname><given-names>P</given-names></name><name><surname>Keam</surname><given-names>S</given-names></name><name><surname>MacKinnon</surname><given-names>KM</given-names></name><name><surname>Cook</surname><given-names>AM</given-names></name><name><surname>Ebert</surname><given-names>MA</given-names></name></person-group><article-title>In vivo noninvasive preclinical tumor hypoxia imaging methods: a review</article-title><source>Int J Radiat Biol</source><year>2021</year><volume>97</volume><issue>5</issue><fpage>593</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">33703994</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toma-Dasu</surname><given-names>I</given-names></name><name><surname>Uhrdin</surname><given-names>J</given-names></name><name><surname>Antonovic</surname><given-names>L</given-names></name><name><surname>Dasu</surname><given-names>A</given-names></name><name><surname>Nuyts</surname><given-names>S</given-names></name><name><surname>Dirix</surname><given-names>P</given-names></name><name><surname>Haustermans</surname><given-names>K</given-names></name><name><surname>Brahme</surname><given-names>A</given-names></name></person-group><article-title>Dose prescription and treatment planning based on fmiso-pet hypoxia</article-title><source>Acta Oncol</source><year>2012</year><volume>51</volume><issue>2</issue><fpage>222</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">21871003</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>NY</given-names></name><name><surname>Mechalakos</surname><given-names>JG</given-names></name><name><surname>Nehmeh</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Squire</surname><given-names>OD</given-names></name><name><surname>Cai</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>K</given-names></name><name><surname>Zanzonico</surname><given-names>PB</given-names></name><name><surname>Greco</surname><given-names>C</given-names></name><name><surname>Ling</surname><given-names>CC</given-names></name><name><surname>Humm</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2008</year><volume>70</volume><issue>1</issue><fpage>2</fpage><lpage>13</lpage><pub-id pub-id-type="pmcid">PMC2888477</pub-id><pub-id pub-id-type="pmid">17869020</pub-id><pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.06.039</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Schoder</surname><given-names>H</given-names></name><name><surname>Beattie</surname><given-names>B</given-names></name><name><surname>Lanning</surname><given-names>R</given-names></name><name><surname>Riaz</surname><given-names>N</given-names></name><name><surname>McBride</surname><given-names>S</given-names></name><name><surname>Katabi</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Yarusi</surname><given-names>B</given-names></name><name><surname>Chan</surname><given-names>S</given-names></name><name><surname>Mitrani</surname><given-names>L</given-names></name><etal/></person-group><article-title>Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human papillomavirus-related oropharyngeal carcinoma</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2016</year><volume>96</volume><issue>1</issue><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="pmcid">PMC5035649</pub-id><pub-id pub-id-type="pmid">27511842</pub-id><pub-id pub-id-type="doi">10.1016/j.ijrobp.2016.04.027</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallac</surname><given-names>Rami R</given-names></name><name><surname>Zhou</surname><given-names>Heling</given-names></name><name><surname>Pidikiti</surname><given-names>Rajesh</given-names></name><name><surname>Song</surname><given-names>Kwang</given-names></name><name><surname>Stojadinovic</surname><given-names>Strahinja</given-names></name><name><surname>Zhao</surname><given-names>Dawen</given-names></name><name><surname>Solberg</surname><given-names>Timothy</given-names></name><name><surname>Peschke</surname><given-names>Peter</given-names></name><name><surname>Mason</surname><given-names>Ralph P</given-names></name></person-group><article-title>Correlations of noninvasive bold and told mri with po2 and relevance to tumor radiation response</article-title><source>Magnetic Resonance in Medicine</source><year>2014</year><volume>71</volume><issue>5</issue><fpage>1863</fpage><lpage>1873</lpage><pub-id pub-id-type="pmcid">PMC3883977</pub-id><pub-id pub-id-type="pmid">23813468</pub-id><pub-id pub-id-type="doi">10.1002/mrm.24846</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadlbauer</surname><given-names>Andreas</given-names></name><name><surname>Zimmermann</surname><given-names>Max</given-names></name><name><surname>Bennani-Baiti</surname><given-names>Barbara</given-names></name><name><surname>Helbich</surname><given-names>Thomas H</given-names></name><name><surname>Baltzer</surname><given-names>Pascal</given-names></name><name><surname>Clauser</surname><given-names>Paola</given-names></name><name><surname>Kapetas</surname><given-names>Panagiotis</given-names></name><name><surname>Bago-Horvath</surname><given-names>Zsuzsanna</given-names></name><name><surname>Pinker</surname><given-names>Katja</given-names></name></person-group><article-title>Development of a non-invasive assessment of hypoxia and neovascularization with magnetic resonance imaging in benign and malignant breast tumors: initial results</article-title><source>Molecular Imaging and Biology</source><year>2019</year><volume>21</volume><fpage>758</fpage><lpage>770</lpage><pub-id pub-id-type="pmcid">PMC7480075</pub-id><pub-id pub-id-type="pmid">30478507</pub-id><pub-id pub-id-type="doi">10.1007/s11307-018-1298-4</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiedenmann</surname><given-names>N</given-names></name><name><surname>Grosu</surname><given-names>AL</given-names></name><name><surname>Buchert</surname><given-names>M</given-names></name><name><surname>Rischke</surname><given-names>HC</given-names></name><name><surname>Ruf</surname><given-names>J</given-names></name><name><surname>Bielak</surname><given-names>L</given-names></name><name><surname>Majerus</surname><given-names>L</given-names></name><name><surname>Ruhle</surname><given-names>A</given-names></name><name><surname>Bamberg</surname><given-names>F</given-names></name><name><surname>Baltas</surname><given-names>D</given-names></name><name><surname>Hennig</surname><given-names>J</given-names></name><etal/></person-group><article-title>The utility of multiparametric mri to characterize hypoxic tumor subvolumes in comparison to fmiso pet/ct. consequences for diagnosis and chemoradiation treatment planning in head and neck cancer</article-title><source>Radiother Oncol</source><year>2020</year><volume>150</volume><fpage>128</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">32544609</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hompland</surname><given-names>T</given-names></name><name><surname>Hole</surname><given-names>KH</given-names></name><name><surname>Ragnum</surname><given-names>HB</given-names></name><name><surname>Aarnes</surname><given-names>EK</given-names></name><name><surname>Vlatkovic</surname><given-names>L</given-names></name><name><surname>Lie</surname><given-names>AK</given-names></name><name><surname>Patzke</surname><given-names>S</given-names></name><name><surname>Brennhovd</surname><given-names>B</given-names></name><name><surname>Seierstad</surname><given-names>T</given-names></name><name><surname>Lyng</surname><given-names>H</given-names></name></person-group><article-title>Combined mr imaging of oxygen consumption and supply reveals tumor hypoxia and aggressiveness in prostate cancer patients</article-title><source>Cancer Res</source><year>2018</year><volume>78</volume><issue>16</issue><fpage>4774</fpage><lpage>4785</lpage><pub-id pub-id-type="pmid">29945958</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillestad</surname><given-names>T</given-names></name><name><surname>Hompland</surname><given-names>T</given-names></name><name><surname>Fjeldbo</surname><given-names>CS</given-names></name><name><surname>Skingen</surname><given-names>VE</given-names></name><name><surname>Salberg</surname><given-names>UB</given-names></name><name><surname>Aarnes</surname><given-names>EK</given-names></name><name><surname>Nilsen</surname><given-names>A</given-names></name><name><surname>Lund</surname><given-names>KV</given-names></name><name><surname>Evensen</surname><given-names>TS</given-names></name><name><surname>Kristensen</surname><given-names>GB</given-names></name><name><surname>Stokke</surname><given-names>T</given-names></name><etal/></person-group><article-title>Mri distinguishes tumor hypoxia levels of different prognostic and biological significance in cervical cancer</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><issue>18</issue><fpage>3993</fpage><lpage>4003</lpage><pub-id pub-id-type="pmid">32606004</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Anna</given-names></name><name><surname>Andersen</surname><given-names>Erlend</given-names></name><name><surname>Lervåg</surname><given-names>Christoffer</given-names></name><name><surname>Julin</surname><given-names>Cathinka H</given-names></name><name><surname>Lyng</surname><given-names>Heidi</given-names></name><name><surname>Hellebust</surname><given-names>Taran P</given-names></name><name><surname>Malinen</surname><given-names>Eirik</given-names></name></person-group><article-title>Dynamic contrast enhanced magnetic resonance imaging for hypoxia mapping and potential for brachytherapy targeting</article-title><source>Physics and Imaging in Radiation Oncology</source><year>2017</year><volume>2</volume><fpage>1</fpage><lpage>6</lpage></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heiken</surname><given-names>JP</given-names></name></person-group><article-title>Contrast safety in the cancer patient: preventing contrast-induced nephropathy</article-title><source>Cancer Imaging</source><year>2008</year><volume>8</volume><issue>Spec Iss A</issue><fpage>S124</fpage><lpage>7</lpage><pub-id pub-id-type="pmcid">PMC2582505</pub-id><pub-id pub-id-type="pmid">18852085</pub-id><pub-id pub-id-type="doi">10.1102/1470-7330.2008.9018</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogosnitzky</surname><given-names>M</given-names></name><name><surname>Branch</surname><given-names>S</given-names></name></person-group><article-title>Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms</article-title><source>Biometals</source><year>2016</year><volume>29</volume><issue>3</issue><fpage>365</fpage><lpage>76</lpage><pub-id pub-id-type="pmcid">PMC4879157</pub-id><pub-id pub-id-type="pmid">27053146</pub-id><pub-id pub-id-type="doi">10.1007/s10534-016-9931-7</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michiels</surname><given-names>C</given-names></name><name><surname>Tellier</surname><given-names>C</given-names></name><name><surname>Feron</surname><given-names>O</given-names></name></person-group><article-title>Cycling hypoxia: A key feature of the tumor microenvironment</article-title><source>Biochim Biophys Acta</source><year>2016</year><volume>1866</volume><issue>1</issue><fpage>76</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">27343712</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Span</surname><given-names>PN</given-names></name><name><surname>Bussink</surname><given-names>J</given-names></name></person-group><article-title>Biology of hypoxia</article-title><source>Semin Nucl Med</source><year>2015</year><volume>45</volume><issue>2</issue><fpage>101</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">25704383</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>TL</given-names></name><name><surname>Brown</surname><given-names>E</given-names></name><name><surname>Hacker</surname><given-names>L</given-names></name><name><surname>Else</surname><given-names>T</given-names></name><name><surname>Oraiopoulou</surname><given-names>ME</given-names></name><name><surname>Tomaszewski</surname><given-names>MR</given-names></name><name><surname>Jena</surname><given-names>R</given-names></name><name><surname>Bohndiek</surname><given-names>SE</given-names></name></person-group><article-title>The potential of photoacoustic imaging in radiation oncology</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><elocation-id>803777</elocation-id><pub-id pub-id-type="pmcid">PMC8928467</pub-id><pub-id pub-id-type="pmid">35311156</pub-id><pub-id pub-id-type="doi">10.3389/fonc.2022.803777</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omar</surname><given-names>M</given-names></name><name><surname>Aguirre</surname><given-names>J</given-names></name><name><surname>Ntziachristos</surname><given-names>V</given-names></name></person-group><article-title>Optoacoustic mesoscopy for biomedicine</article-title><source>Nat Biomed Eng</source><year>2019</year><volume>3</volume><issue>5</issue><fpage>354</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">30988470</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor-Williams</surname><given-names>Michaela</given-names></name><name><surname>Spicer</surname><given-names>Graham</given-names></name><name><surname>Bale</surname><given-names>Gemma</given-names></name><name><surname>Bohndiek</surname><given-names>Sarah E</given-names></name></person-group><article-title>Noninvasive hemoglobin sensing and imaging: optical tools for disease diagnosis</article-title><source>Journal of Biomedical Optics</source><year>2022</year><volume>27</volume><issue>8</issue><elocation-id>080901</elocation-id><pub-id pub-id-type="pmcid">PMC9346606</pub-id><pub-id pub-id-type="pmid">35922891</pub-id><pub-id pub-id-type="doi">10.1117/1.JBO.27.8.080901</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>E</given-names></name><name><surname>Brunker</surname><given-names>J</given-names></name><name><surname>Bohndiek</surname><given-names>SE</given-names></name></person-group><article-title>Photoacoustic imaging as a tool to probe the tumour microenvironment</article-title><source>Dis Model Mech</source><year>2019</year><volume>12</volume><issue>7</issue><pub-id pub-id-type="pmcid">PMC6679374</pub-id><pub-id pub-id-type="pmid">31337635</pub-id><pub-id pub-id-type="doi">10.1242/dmm.039636</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomaszewski</surname><given-names>MR</given-names></name><name><surname>Gonzalez</surname><given-names>IQ</given-names></name><name><surname>O’Connor</surname><given-names>JP</given-names></name><name><surname>Abeyakoon</surname><given-names>O</given-names></name><name><surname>Parker</surname><given-names>GJ</given-names></name><name><surname>Williams</surname><given-names>KJ</given-names></name><name><surname>Gilbert</surname><given-names>FJ</given-names></name><name><surname>Bohndiek</surname><given-names>SE</given-names></name></person-group><article-title>Oxygen enhanced optoacoustic tomography (oe-ot) reveals vascular dynamics in murine models of prostate cancer</article-title><source>Theranostics</source><year>2017</year><volume>7</volume><issue>11</issue><fpage>2900</fpage><lpage>2913</lpage><pub-id pub-id-type="pmcid">PMC5562224</pub-id><pub-id pub-id-type="pmid">28824724</pub-id><pub-id pub-id-type="doi">10.7150/thno.19841</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omar</surname><given-names>M</given-names></name><name><surname>Gateau</surname><given-names>J</given-names></name><name><surname>Ntziachristos</surname><given-names>V</given-names></name></person-group><article-title>Raster-scan optoacoustic mesoscopy in the 25-125 mhz range</article-title><source>Opt Lett</source><year>2013</year><volume>38</volume><issue>14</issue><fpage>2472</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">23939084</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rich</surname><given-names>LJ</given-names></name><name><surname>Seshadri</surname><given-names>M</given-names></name></person-group><article-title>Photoacoustic monitoring of tumor and normal tissue response to radiation</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><elocation-id>21237</elocation-id><pub-id pub-id-type="pmcid">PMC4756329</pub-id><pub-id pub-id-type="pmid">26883660</pub-id><pub-id pub-id-type="doi">10.1038/srep21237</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rich</surname><given-names>LJ</given-names></name><name><surname>Miller</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Seshadri</surname><given-names>M</given-names></name></person-group><article-title>Photoacoustic imaging as an early biomarker of radio therapeutic efficacy in head and neck cancer</article-title><source>Theranostics</source><year>2018</year><volume>8</volume><issue>8</issue><fpage>2064</fpage><lpage>2078</lpage><pub-id pub-id-type="pmcid">PMC5928871</pub-id><pub-id pub-id-type="pmid">29721063</pub-id><pub-id pub-id-type="doi">10.7150/thno.21708</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orlova</surname><given-names>Anna</given-names></name><name><surname>Pavlova</surname><given-names>Ksenia</given-names></name><name><surname>Kurnikov</surname><given-names>Aleksey</given-names></name><name><surname>Maslennikova</surname><given-names>Anna</given-names></name><name><surname>Myagcheva</surname><given-names>Marina</given-names></name><name><surname>Zakharov</surname><given-names>Evgeniy</given-names></name><name><surname>Skamnitskiy</surname><given-names>Dmitry</given-names></name><name><surname>Perekatova</surname><given-names>Valeria</given-names></name><name><surname>Khilov</surname><given-names>Alexander</given-names></name><name><surname>Kovalchuk</surname><given-names>Andrey</given-names></name><name><surname>Moiseev</surname><given-names>Alexander</given-names></name><etal/></person-group><article-title>Noninvasive optoacoustic microangiography reveals dose and size dependency of radiation-induced deep tumor vasculature remodeling</article-title><source>Neoplasia</source><year>2022</year><volume>26</volume><elocation-id>100778</elocation-id><pub-id pub-id-type="pmcid">PMC8889238</pub-id><pub-id pub-id-type="pmid">35220045</pub-id><pub-id pub-id-type="doi">10.1016/j.neo.2022.100778</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Zhongli</given-names></name><name><surname>Chen</surname><given-names>Zhuo</given-names></name><name><surname>Bailey</surname><given-names>Kristy E</given-names></name><name><surname>Scollard</surname><given-names>Deborah A</given-names></name><name><surname>Reilly</surname><given-names>Raymond M</given-names></name><name><surname>Vallis</surname><given-names>Katherine A</given-names></name></person-group><article-title>Relationship between induction of phosphorylated h2ax and survival in breast cancer cells exposed to 111in-dtpa-hegf</article-title><source>Journal of Nuclear Medicine</source><year>2008</year><volume>49</volume><issue>8</issue><fpage>1353</fpage><lpage>1361</lpage><pub-id pub-id-type="pmid">18632822</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eschrich</surname><given-names>Steven</given-names></name><name><surname>Zhang</surname><given-names>Hongling</given-names></name><name><surname>Zhao</surname><given-names>Haiyan</given-names></name><name><surname>Boulware</surname><given-names>David</given-names></name><name><surname>Lee</surname><given-names>Ji-Hyun</given-names></name><name><surname>Bloom</surname><given-names>Gregory</given-names></name><name><surname>Torres-Roca</surname><given-names>Javier F</given-names></name></person-group><article-title>Systems biology modeling of the radiation sensitivity network: A biomarker discovery platform</article-title><source>International Journal of Radiation Oncology*Biology*Physics</source><year>2009</year><volume>75</volume><issue>2</issue><fpage>497</fpage><lpage>505</lpage><pub-id pub-id-type="pmcid">PMC2762403</pub-id><pub-id pub-id-type="pmid">19735874</pub-id><pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.05.056</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villalobos</surname><given-names>M</given-names></name></person-group><article-title>Radiosensitivity of human breast cancer cell lines of different hormonal responsiveness. modulatory effects of oestradiol</article-title><source>International Journal of Radiation Biology</source><year>1996</year><volume>70</volume><issue>2</issue><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">8794845</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amorino</surname><given-names>George P</given-names></name><name><surname>Freeman</surname><given-names>Michael L</given-names></name><name><surname>Choy</surname><given-names>Hak</given-names></name></person-group><article-title>Enhancement of Radiation Effects In Vitro by the Estrogen Metabolite 2-Methoxyestradiol</article-title><source>Radiation Research</source><year>2000</year><volume>153</volume><issue>4</issue><fpage>384</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">10760997</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quiros-Gonzalez</surname><given-names>I</given-names></name><name><surname>Tomaszewski</surname><given-names>MR</given-names></name><name><surname>Aitken</surname><given-names>SJ</given-names></name><name><surname>Ansel-Bollepalli</surname><given-names>L</given-names></name><name><surname>McDuffus</surname><given-names>LA</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Hacker</surname><given-names>L</given-names></name><name><surname>Brunker</surname><given-names>J</given-names></name><name><surname>Bohndiek</surname><given-names>SE</given-names></name></person-group><article-title>Optoacoustics delineates murine breast cancer models displaying angiogenesis and vascular mimicry</article-title><source>Br J Cancer</source><year>2018</year><volume>118</volume><issue>8</issue><fpage>1098</fpage><lpage>1106</lpage><pub-id pub-id-type="pmcid">PMC5931091</pub-id><pub-id pub-id-type="pmid">29576623</pub-id><pub-id pub-id-type="doi">10.1038/s41416-018-0033-x</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinwa</surname><given-names>P</given-names></name><name><surname>Eriksson</surname><given-names>M</given-names></name><name><surname>Cotgreave</surname><given-names>I</given-names></name><name><surname>Bäckberg</surname><given-names>M</given-names></name></person-group><article-title>3r-refinement principles: elevating rodent well-being and research quality</article-title><source>Lab Anim Res</source><year>2024</year><volume>40</volume><issue>1</issue><fpage>11</fpage><pub-id pub-id-type="pmcid">PMC10979584</pub-id><pub-id pub-id-type="pmid">38549171</pub-id><pub-id pub-id-type="doi">10.1186/s42826-024-00198-3</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sittadjody</surname><given-names>Sivanandane</given-names></name></person-group><chapter-title>Controlled release of hormones by pellet implants</chapter-title><source>Controlled Drug Delivery Systems</source><publisher-name>CRC Press</publisher-name><year>2020</year><fpage>91</fpage><lpage>107</lpage></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gates</surname><given-names>KV</given-names></name><name><surname>Alamaw</surname><given-names>E</given-names></name><name><surname>Jampachaisri</surname><given-names>K</given-names></name><name><surname>Huss</surname><given-names>MK</given-names></name><name><surname>Pacharinsak</surname><given-names>C</given-names></name></person-group><article-title>Efficacy of supplemental diet gels for preventing postoperative weight loss in mice (mus musculus)</article-title><source>J Am Assoc Lab Anim Sci</source><year>2023</year><volume>62</volume><issue>1</issue><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="pmcid">PMC9936848</pub-id><pub-id pub-id-type="pmid">36410729</pub-id><pub-id pub-id-type="doi">10.30802/AALAS-JAALAS22-000030</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>CM</given-names></name><name><surname>Coffey</surname><given-names>CW</given-names></name><name><surname>DeWerd</surname><given-names>LA</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Nath</surname><given-names>R</given-names></name><name><surname>Seltzer</surname><given-names>SM</given-names></name><name><surname>Seuntjens</surname><given-names>JP</given-names></name><collab>Medicine American Association of Physicists in</collab></person-group><article-title>Aapm protocol for 40-300 kv x-ray beam dosimetry in radiotherapy and radiobiology</article-title><source>Med Phys</source><year>2001</year><volume>28</volume><issue>6</issue><fpage>868</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">11439485</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraass</surname><given-names>B</given-names></name><name><surname>Doppke</surname><given-names>K</given-names></name><name><surname>Hunt</surname><given-names>M</given-names></name><name><surname>Kutcher</surname><given-names>G</given-names></name><name><surname>Starkschall</surname><given-names>G</given-names></name><name><surname>Stern</surname><given-names>R</given-names></name><name><surname>Van Dyke</surname><given-names>J</given-names></name></person-group><article-title>American association of physicists in medicine radiation therapy committee task group 53: quality assurance for clinical radiotherapy treatment planning</article-title><source>Med Phys</source><year>1998</year><volume>25</volume><issue>10</issue><fpage>1773</fpage><lpage>829</lpage><pub-id pub-id-type="pmid">9800687</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsay</surname><given-names>PE</given-names></name><name><surname>Granton</surname><given-names>PV</given-names></name><name><surname>Gasparini</surname><given-names>A</given-names></name><name><surname>Jelveh</surname><given-names>S</given-names></name><name><surname>Clarkson</surname><given-names>R</given-names></name><name><surname>van Hoof</surname><given-names>S</given-names></name><name><surname>Hermans</surname><given-names>J</given-names></name><name><surname>Kaas</surname><given-names>J</given-names></name><name><surname>Wittkamper</surname><given-names>F</given-names></name><name><surname>Sonke</surname><given-names>JJ</given-names></name><name><surname>Verhaegen</surname><given-names>F</given-names></name><etal/></person-group><article-title>Multi-institutional dosimetric and geometric commissioning of image-guided small animal irradiators</article-title><source>Med Phys</source><year>2014</year><volume>41</volume><issue>3</issue><elocation-id>031714</elocation-id><pub-id pub-id-type="pmid">24593718</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>J</given-names></name><name><surname>Armour</surname><given-names>E</given-names></name><name><surname>Kazanzides</surname><given-names>P</given-names></name><name><surname>Iordachita</surname><given-names>I</given-names></name><name><surname>Tryggestad</surname><given-names>E</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Matinfar</surname><given-names>M</given-names></name><name><surname>Kennedy</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Chan</surname><given-names>T</given-names></name><name><surname>Gray</surname><given-names>O</given-names></name><etal/></person-group><article-title>High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2008</year><volume>71</volume><issue>5</issue><fpage>1591</fpage><lpage>9</lpage><pub-id pub-id-type="pmcid">PMC2605655</pub-id><pub-id pub-id-type="pmid">18640502</pub-id><pub-id pub-id-type="doi">10.1016/j.ijrobp.2008.04.025</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacques</surname><given-names>Robert</given-names></name><name><surname>Taylor</surname><given-names>Russell</given-names></name><name><surname>Wong</surname><given-names>John</given-names></name><name><surname>McNutt</surname><given-names>Todd</given-names></name></person-group><article-title>Towards real-time radiation therapy: Gpu accelerated superposition/convolution</article-title><source>Computer Methods and Programs in Biomedicine</source><year>2010</year><volume>98</volume><issue>3</issue><fpage>285</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">19695731</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacques</surname><given-names>Robert</given-names></name><name><surname>Wong</surname><given-names>John</given-names></name><name><surname>Taylor</surname><given-names>Russell</given-names></name><name><surname>McNutt</surname><given-names>Todd</given-names></name></person-group><article-title>Real-time dose computation: Gpu-accelerated source modeling and superposition/convolution</article-title><source>Medical Physics</source><year>2011</year><volume>38</volume><issue>1</issue><fpage>294</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">21361198</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavigne</surname><given-names>Danny</given-names></name><name><surname>Hijal</surname><given-names>Tarek</given-names></name><name><surname>Vavassis</surname><given-names>Peter</given-names></name><name><surname>Guilbert</surname><given-names>Marie-Christine</given-names></name><name><surname>Sideris</surname><given-names>Lucas</given-names></name><name><surname>Dubé</surname><given-names>Pierre</given-names></name><name><surname>Gervais</surname><given-names>Mai-Kim</given-names></name><name><surname>Leblanc</surname><given-names>Guy</given-names></name><name><surname>Dufresne</surname><given-names>Michel-Pierre</given-names></name><name><surname>Nguyen</surname><given-names>David</given-names></name><name><surname>Tiberi</surname><given-names>David</given-names></name><etal/></person-group><article-title>Single preoperative radiation therapy with delayed surgery for low-risk breast cancer: Oncologic outcome, toxicity and cosmesis of the sport-ds phase i trial</article-title><source>Radiotherapy and Oncology</source><year>2024</year><volume>200</volume><elocation-id>110515</elocation-id><pub-id pub-id-type="pmid">39218041</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Civil</surname><given-names>Yasmin A</given-names></name><name><surname>Vasmel</surname><given-names>Jeanine E</given-names></name><name><surname>Charaghvandi</surname><given-names>Ramona K</given-names></name><name><surname>Houweling</surname><given-names>Anette C</given-names></name><name><surname>Vreuls</surname><given-names>Celien PH</given-names></name><name><surname>van Diest</surname><given-names>Paul J</given-names></name><name><surname>Witkamp</surname><given-names>Arjen J</given-names></name><name><surname>Doeksen</surname><given-names>Annemiek</given-names></name><name><surname>van Dalen</surname><given-names>Thijs</given-names></name><name><surname>Felderhof</surname><given-names>Joeke</given-names></name><name><surname>van Dam</surname><given-names>Iris</given-names></name><etal/></person-group><article-title>Preoperative magnetic resonance guided single-dose partial breast irradiation: 5-year results of the prospective single-arm ablative trial</article-title><source>International Journal of Radiation Oncology*Biology*Physics</source><year>2024</year><pub-id pub-id-type="pmid">39098432</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidolin</surname><given-names>K</given-names></name><name><surname>Yaremko</surname><given-names>B</given-names></name><name><surname>Lynn</surname><given-names>K</given-names></name><name><surname>Gaede</surname><given-names>S</given-names></name><name><surname>Kornecki</surname><given-names>A</given-names></name><name><surname>Muscedere</surname><given-names>G</given-names></name><name><surname>BenNachum</surname><given-names>I</given-names></name><name><surname>Shmuilovich</surname><given-names>O</given-names></name><name><surname>Mouawad</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>E</given-names></name><name><surname>Sexton</surname><given-names>T</given-names></name><etal/></person-group><article-title>Stereotactic image-guided neoadjuvant ablative single-dose radiation, then lumpectomy, for early breast cancer: the signal prospective single-arm trial of single-dose radiation therapy</article-title><source>Curr Oncol</source><year>2019</year><volume>26</volume><issue>3</issue><fpage>e334</fpage><lpage>e340</lpage><pub-id pub-id-type="pmcid">PMC6588073</pub-id><pub-id pub-id-type="pmid">31285677</pub-id><pub-id pub-id-type="doi">10.3747/co.26.4479</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Civil</surname><given-names>Yasmin A</given-names></name><name><surname>Oei</surname><given-names>Arlene L</given-names></name><name><surname>Duvivier</surname><given-names>Katya M</given-names></name><name><surname>Bijker</surname><given-names>Nina</given-names></name><name><surname>Meijnen</surname><given-names>Philip</given-names></name><name><surname>Donkers</surname><given-names>Lorraine</given-names></name><name><surname>Verheijen</surname><given-names>Sonja</given-names></name><name><surname>van Kesteren</surname><given-names>Zdenko</given-names></name><name><surname>Palacios</surname><given-names>Miguel A</given-names></name><name><surname>Schijf</surname><given-names>Laura J</given-names></name><name><surname>Barba</surname><given-names>Ellis</given-names></name><etal/></person-group><article-title>Prediction of pathologic complete response after single-dose mr-guided partial breast irradiation in low-risk breast cancer patients: the ablative-2 trial: a study protocol</article-title><source>BMC Cancer</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>419</fpage><pub-id pub-id-type="pmcid">PMC10169374</pub-id><pub-id pub-id-type="pmid">37161377</pub-id><pub-id pub-id-type="doi">10.1186/s12885-023-10910-6</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zerella</surname><given-names>Maria Alessia</given-names></name><name><surname>Zaffaroni</surname><given-names>Mattia</given-names></name><name><surname>Ronci</surname><given-names>Giuseppe</given-names></name><name><surname>Dicuonzo</surname><given-names>Samantha</given-names></name><name><surname>Rojas</surname><given-names>Damaris Patricia</given-names></name><name><surname>Morra</surname><given-names>Anna</given-names></name><name><surname>Fodor</surname><given-names>Cristiana</given-names></name><name><surname>Rondi</surname><given-names>Elena</given-names></name><name><surname>Vigorito</surname><given-names>Sabrina</given-names></name><name><surname>Botta</surname><given-names>Francesca</given-names></name><name><surname>Cremonesi</surname><given-names>Marta</given-names></name><etal/></person-group><article-title>Single fraction ablative preoperative radiation treatment for early-stage breast cancer: the crystal study a phase i/ii clinical trial protocol</article-title><source>BMC Cancer</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>358</fpage><pub-id pub-id-type="pmcid">PMC8977020</pub-id><pub-id pub-id-type="pmid">35366825</pub-id><pub-id pub-id-type="doi">10.1186/s12885-022-09305-w</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray Brunt</surname><given-names>A</given-names></name><name><surname>Haviland</surname><given-names>JS</given-names></name><name><surname>Wheatley</surname><given-names>DA</given-names></name><name><surname>Sydenham</surname><given-names>MA</given-names></name><name><surname>Alhasso</surname><given-names>A</given-names></name><name><surname>Bloomfield</surname><given-names>DJ</given-names></name><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Churn</surname><given-names>M</given-names></name><name><surname>Cleator</surname><given-names>S</given-names></name><name><surname>Coles</surname><given-names>CE</given-names></name><name><surname>Goodman</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hypofractionated breast radiotherapy for 1 week versus 3 weeks (fast-forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10237</issue><fpage>1613</fpage><lpage>1626</lpage><pub-id pub-id-type="pmcid">PMC7262592</pub-id><pub-id pub-id-type="pmid">32580883</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30932-6</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Karpiouk</surname><given-names>AB</given-names></name><name><surname>Aglyamov</surname><given-names>SR</given-names></name><name><surname>Emelianov</surname><given-names>SY</given-names></name></person-group><article-title>Adaptive beamforming for photoacoustic imaging</article-title><source>Opt Lett</source><year>2008</year><volume>33</volume><issue>12</issue><fpage>1291</fpage><lpage>3</lpage><pub-id pub-id-type="pmcid">PMC2713818</pub-id><pub-id pub-id-type="pmid">18552935</pub-id><pub-id pub-id-type="doi">10.1364/ol.33.001291</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omar</surname><given-names>M</given-names></name><name><surname>Soliman</surname><given-names>D</given-names></name><name><surname>Gateau</surname><given-names>J</given-names></name><name><surname>Ntziachristos</surname><given-names>V</given-names></name></person-group><article-title>Ultrawideband reflection-mode optoacoustic mesoscopy</article-title><source>Opt Lett</source><year>2014</year><volume>39</volume><issue>13</issue><fpage>3911</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">24978769</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeney</surname><given-names>Paul W</given-names></name><name><surname>Hacker</surname><given-names>Lina</given-names></name><name><surname>Lefebvre</surname><given-names>Thierry L</given-names></name><name><surname>Brown</surname><given-names>Emma L</given-names></name><name><surname>Grohl</surname><given-names>Janek</given-names></name><name><surname>Bohndiek</surname><given-names>Sarah E</given-names></name></person-group><article-title>Unsupervised segmentation of 3d microvascular photoacoustic images using deep generative learning</article-title><source>Advanced Science</source><year>2024</year><volume>11</volume><issue>32</issue><elocation-id>2402195</elocation-id><pub-id pub-id-type="pmcid">PMC11348209</pub-id><pub-id pub-id-type="pmid">38923324</pub-id><pub-id pub-id-type="doi">10.1002/advs.202402195</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>EL</given-names></name><name><surname>Lefebvre</surname><given-names>TL</given-names></name><name><surname>Sweeney</surname><given-names>PW</given-names></name><name><surname>Stolz</surname><given-names>BJ</given-names></name><name><surname>Grohl</surname><given-names>J</given-names></name><name><surname>Hacker</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Couturier</surname><given-names>DL</given-names></name><name><surname>Harrington</surname><given-names>HA</given-names></name><name><surname>Byrne</surname><given-names>HM</given-names></name><name><surname>Bohndiek</surname><given-names>SE</given-names></name></person-group><article-title>Quantification of vascular networks in photoacoustic mesoscopy</article-title><source>Photoacoustics</source><year>2022</year><volume>26</volume><elocation-id>100357</elocation-id><pub-id pub-id-type="pmcid">PMC9095888</pub-id><pub-id pub-id-type="pmid">35574188</pub-id><pub-id pub-id-type="doi">10.1016/j.pacs.2022.100357</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stolz</surname><given-names>Bernadette J</given-names></name><name><surname>Kaeppler</surname><given-names>Jakob</given-names></name><name><surname>Markelc</surname><given-names>Bostjan</given-names></name><name><surname>Braun</surname><given-names>Franziska</given-names></name><name><surname>Lipsmeier</surname><given-names>Florian</given-names></name><name><surname>Muschel</surname><given-names>Ruth J</given-names></name><name><surname>Byrne</surname><given-names>Helen M</given-names></name><name><surname>Harrington</surname><given-names>Heather A</given-names></name></person-group><article-title>Multiscale topology characterizes dynamic tumor vascular networks</article-title><source>Science Advances</source><year>2022</year><volume>8</volume><issue>23</issue><elocation-id>eabm2456</elocation-id><pub-id pub-id-type="pmcid">PMC9187234</pub-id><pub-id pub-id-type="pmid">35687679</pub-id><pub-id pub-id-type="doi">10.1126/sciadv.abm2456</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Else</surname><given-names>Thomas R</given-names></name><name><surname>Grohl</surname><given-names>Janek</given-names></name><name><surname>Hacker</surname><given-names>Lina</given-names></name><name><surname>Bohndiek</surname><given-names>Sarah E</given-names></name></person-group><article-title>Patato: a python photoacoustic tomography analysis toolkit</article-title><source>Journal of Open Source Software</source><year>2024</year><volume>9</volume><issue>93</issue><elocation-id>5686</elocation-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holm</surname><given-names>Sture</given-names></name></person-group><article-title>A simple sequentially rejective multiple test procedure</article-title><source>Scandinavian Journal of Statistics</source><year>1979</year><volume>6</volume><issue>2</issue><fpage>65</fpage><lpage>70</lpage></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draeger</surname><given-names>E</given-names></name><name><surname>Sawant</surname><given-names>A</given-names></name><name><surname>Johnstone</surname><given-names>C</given-names></name><name><surname>Koger</surname><given-names>B</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Vujaskovic</surname><given-names>Z</given-names></name><name><surname>Jackson</surname><given-names>IL</given-names></name><name><surname>Poirier</surname><given-names>Y</given-names></name></person-group><article-title>A dose of reality: How 20 years of incomplete physics and dosimetry reporting in radiobiology studies may have contributed to the reproducibility crisis</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2020</year><volume>106</volume><issue>2</issue><fpage>243</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">31288053</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartsch</surname><given-names>Silvester J</given-names></name><name><surname>Brozova</surname><given-names>Klara</given-names></name><name><surname>Ehret</surname><given-names>Viktoria</given-names></name><name><surname>Friske</surname><given-names>Joachim</given-names></name><name><surname>Furbock</surname><given-names>Christoph</given-names></name><name><surname>Kenner</surname><given-names>Lukas</given-names></name><name><surname>Laimer-Gruber</surname><given-names>Daniela</given-names></name><name><surname>Helbich</surname><given-names>Thomas H</given-names></name><name><surname>Pinker</surname><given-names>Katja</given-names></name></person-group><article-title>Non-contrast-enhanced multiparametric mri of the hypoxic tumor microenvironment allows molecular subtyping of breast cancer: A pilot study</article-title><source>Cancers</source><year>2024</year><volume>16</volume><issue>2</issue><pub-id pub-id-type="pmcid">PMC10813988</pub-id><pub-id pub-id-type="pmid">38254864</pub-id><pub-id pub-id-type="doi">10.3390/cancers16020375</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Chen-Ting</given-names></name><name><surname>Zhou</surname><given-names>Yingchun</given-names></name><name><surname>Roy-Choudhury</surname><given-names>Kingshuk</given-names></name><name><surname>Siamakpour-Reihani</surname><given-names>Sharareh</given-names></name><name><surname>Young</surname><given-names>Kenneth</given-names></name><name><surname>Hoang</surname><given-names>Peter</given-names></name><name><surname>Kirkpatrick</surname><given-names>John P</given-names></name><name><surname>Chi</surname><given-names>Jen-Tsan A</given-names></name><name><surname>Dewhirst</surname><given-names>Mark W</given-names></name><name><surname>Horton</surname><given-names>Janet K</given-names></name></person-group><article-title>Subtype-Specific Radiation Response and Therapeutic Effect of FAS Death Receptor Modulation in Human Breast Cancer</article-title><source>Radiation Research</source><year>2017</year><volume>188</volume><issue>2</issue><fpage>169</fpage><lpage>180</lpage><pub-id pub-id-type="pmcid">PMC5816985</pub-id><pub-id pub-id-type="pmid">28598289</pub-id><pub-id pub-id-type="doi">10.1667/RR14664.1</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>JM</given-names></name><name><surname>Miller</surname><given-names>TC</given-names></name><name><surname>Meyer</surname><given-names>MJ</given-names></name><name><surname>Ginsburg</surname><given-names>E</given-names></name><name><surname>Vonderhaar</surname><given-names>BK</given-names></name></person-group><article-title>Local regulation of human breast xenograft models</article-title><source>J Cell Physiol</source><year>2010</year><volume>224</volume><issue>3</issue><fpage>795</fpage><lpage>806</lpage><pub-id pub-id-type="pmcid">PMC2897719</pub-id><pub-id pub-id-type="pmid">20578247</pub-id><pub-id pub-id-type="doi">10.1002/jcp.22190</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>Márcia Martinho</given-names></name><name><surname>Shah</surname><given-names>Anant</given-names></name><name><surname>Rivens</surname><given-names>Ian</given-names></name><name><surname>Box</surname><given-names>Carol</given-names></name><name><surname>O’Shea</surname><given-names>Tuathan</given-names></name><name><surname>Bamber</surname><given-names>Jeffrey</given-names></name><name><surname>ter Haar</surname><given-names>Gail</given-names></name></person-group><article-title>Photoacoustic imaging for the prediction and assessment of response to radiotherapy in vivo</article-title><source>bioRxiv</source><year>2018</year><elocation-id>329516</elocation-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>Shreya</given-names></name><name><surname>de la Cerda</surname><given-names>Jorge</given-names></name><name><surname>Schuler</surname><given-names>William</given-names></name><name><surname>Kotrotsou</surname><given-names>Aikaterini</given-names></name><name><surname>Cardenas-Rodriguez</surname><given-names>Julio</given-names></name><name><surname>Pagel</surname><given-names>Mark</given-names></name></person-group><source>Evaluations of radiotherapy in small animal models of pancreatic cancer with oxygen enhanced–dynamic contrast enhanced multispectral optoacoustic tomography (OE-DCE MSOT)</source><conf-name>Photons Plus Ultrasound: Imaging and Sensing 2023</conf-name><conf-sponsor>International Society for Optics and Photonics, SPIE</conf-sponsor><year>2023</year><volume>12379</volume><elocation-id>123791B</elocation-id><pub-id pub-id-type="doi">10.1117/12.2648074</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>Janggun</given-names></name><name><surname>Folz</surname><given-names>Jeff</given-names></name><name><surname>Gonzalez</surname><given-names>Maria E</given-names></name><name><surname>Paolo</surname><given-names>Alessandro</given-names></name><name><surname>Eido</surname><given-names>Ahmad</given-names></name><name><surname>Salfi</surname><given-names>Eamon</given-names></name><name><surname>Tekula</surname><given-names>Shilpa</given-names></name><name><surname>And</surname><given-names>Sebastiano</given-names></name><name><surname>Caruso</surname><given-names>Roberta</given-names></name><name><surname>Kleer</surname><given-names>Celina G</given-names></name><name><surname>Wang</surname><given-names>Xueding</given-names></name><etal/></person-group><article-title>Personalized oncology by in vivo chemical imaging: Photoacoustic mapping of tumor oxygen predicts radiotherapy efficacy</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><issue>5</issue><fpage>4396</fpage><lpage>4403</lpage><pub-id pub-id-type="pmcid">PMC10149113</pub-id><pub-id pub-id-type="pmid">36847392</pub-id><pub-id pub-id-type="doi">10.1021/acsnano.2c09502</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>de la Cerda</surname><given-names>J</given-names></name><name><surname>Schuler</surname><given-names>W</given-names></name><name><surname>Kotrotsou</surname><given-names>A</given-names></name><name><surname>Cárdenas-Rodríguez</surname><given-names>J</given-names></name><name><surname>Pagel</surname><given-names>MD</given-names></name></person-group><article-title>Improving evaluations of radiation therapy with dynamic contrast enhanced multispectral optoacoustic tomography (dce msot)</article-title><source>Proceedings of the European Molecular Imaging Meeting</source><year>2020</year><fpage>09</fpage><lpage>03</lpage></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bussink</surname><given-names>J</given-names></name><name><surname>Kaanders</surname><given-names>JHAM</given-names></name><name><surname>Rijken</surname><given-names>PFJW</given-names></name><name><surname>Raleigh</surname><given-names>JA</given-names></name><name><surname>Van der Kogel</surname><given-names>AJ</given-names></name></person-group><article-title>Changes in blood perfusion and hypoxia after irradiation of a human squamous cell carcinoma xenograft tumor line</article-title><source>Radiation Research</source><year>2000</year><volume>153</volume><issue>4</issue><fpage>398</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">10760999</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kory</surname><given-names>J</given-names></name><name><surname>Narain</surname><given-names>V</given-names></name><name><surname>Stolz</surname><given-names>BJ</given-names></name><name><surname>Kaeppler</surname><given-names>J</given-names></name><name><surname>Markelc</surname><given-names>B</given-names></name><name><surname>Muschel</surname><given-names>RJ</given-names></name><name><surname>Maini</surname><given-names>PK</given-names></name><name><surname>Pitt-Francis</surname><given-names>JM</given-names></name><name><surname>Byrne</surname><given-names>HM</given-names></name></person-group><article-title>Enhanced perfusion following exposure to radiotherapy: A theoretical investigation</article-title><source>PLoS Comput Biol</source><year>2024</year><volume>20</volume><issue>2</issue><elocation-id>e1011252</elocation-id><pub-id pub-id-type="pmcid">PMC10903964</pub-id><pub-id pub-id-type="pmid">38363799</pub-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1011252</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orlova</surname><given-names>A</given-names></name><name><surname>Sirotkina</surname><given-names>M</given-names></name><name><surname>Smolina</surname><given-names>E</given-names></name><name><surname>Elagin</surname><given-names>V</given-names></name><name><surname>Kovalchuk</surname><given-names>A</given-names></name><name><surname>Turchin</surname><given-names>I</given-names></name><name><surname>Subochev</surname><given-names>P</given-names></name></person-group><article-title>Raster-scan optoacoustic angiography of blood vessel development in colon cancer models</article-title><source>Photoacoustics</source><year>2019</year><volume>13</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="pmcid">PMC6275215</pub-id><pub-id pub-id-type="pmid">30555784</pub-id><pub-id pub-id-type="doi">10.1016/j.pacs.2018.11.005</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaeppler</surname><given-names>Jakob R</given-names></name><name><surname>Chen</surname><given-names>Jianzhou</given-names></name><name><surname>Buono</surname><given-names>Mario</given-names></name><name><surname>Vermeer</surname><given-names>Jenny</given-names></name><name><surname>Kannan</surname><given-names>Pavitra</given-names></name><name><surname>Cheng</surname><given-names>WeiâCChen</given-names></name><name><surname>Voukantsis</surname><given-names>Dimitrios</given-names></name><name><surname>Thompson</surname><given-names>James M</given-names></name><name><surname>Hill</surname><given-names>Mark A</given-names></name><name><surname>Allen</surname><given-names>Danny</given-names></name><name><surname>Gomes</surname><given-names>Ana</given-names></name><etal/></person-group><article-title>Endothelial cell death after ionizing radiation does not impair vascular structure in mouse tumor models</article-title><source>EMBO reports</source><year>2022</year><volume>23</volume><issue>9</issue><elocation-id>e53221</elocation-id><pub-id pub-id-type="pmcid">PMC9442312</pub-id><pub-id pub-id-type="pmid">35848459</pub-id><pub-id pub-id-type="doi">10.15252/embr.202153221</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysi</surname><given-names>E</given-names></name><name><surname>Fadhel</surname><given-names>MN</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sebastian</surname><given-names>JA</given-names></name><name><surname>Giles</surname><given-names>A</given-names></name><name><surname>Czarnota</surname><given-names>GJ</given-names></name><name><surname>Exner</surname><given-names>AA</given-names></name><name><surname>Kolios</surname><given-names>MC</given-names></name></person-group><article-title>Photoacoustic imaging biomarkers for monitoring biophysical changes during nanobubble-mediated radiation treatment</article-title><source>Photoacoustics</source><year>2020</year><volume>20</volume><elocation-id>100201</elocation-id><pub-id pub-id-type="pmcid">PMC7393572</pub-id><pub-id pub-id-type="pmid">32775198</pub-id><pub-id pub-id-type="doi">10.1016/j.pacs.2020.100201</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Xu</given-names></name><name><surname>Allu</surname><given-names>Srinivasa Rao</given-names></name><name><surname>Jiang</surname><given-names>Shudong</given-names></name><name><surname>Jia</surname><given-names>Mengyu</given-names></name><name><surname>Gunn</surname><given-names>Jason R</given-names></name><name><surname>Yao</surname><given-names>Cuiping</given-names></name><name><surname>LaRochelle</surname><given-names>Ethan P</given-names></name><name><surname>Shell</surname><given-names>Jennifer R</given-names></name><name><surname>Bruza</surname><given-names>Petr</given-names></name><name><surname>Gladstone</surname><given-names>David J</given-names></name><name><surname>Jarvis</surname><given-names>Lesley A</given-names></name><etal/></person-group><article-title>Tissue po2 distributions in xenograft tumors dynamically imaged by cherenkov-excited phosphorescence during fractionated radiation therapy</article-title><source>Nature Communications</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>573</fpage><pub-id pub-id-type="pmcid">PMC6989492</pub-id><pub-id pub-id-type="pmid">31996677</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-14415-9</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>J</given-names></name><name><surname>Tomaszewski</surname><given-names>MR</given-names></name><name><surname>Quiros-Gonzalez</surname><given-names>I</given-names></name><name><surname>Weber</surname><given-names>J</given-names></name><name><surname>Brunker</surname><given-names>J</given-names></name><name><surname>Bohndiek</surname><given-names>SE</given-names></name></person-group><article-title>Evaluation of precision in optoacoustic tomography for preclinical imaging in living subjects</article-title><source>J Nucl Med</source><year>2017</year><volume>58</volume><issue>5</issue><fpage>807</fpage><lpage>814</lpage><pub-id pub-id-type="pmid">28126890</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poirier</surname><given-names>Y</given-names></name><name><surname>Johnstone</surname><given-names>CD</given-names></name><name><surname>Anvari</surname><given-names>A</given-names></name><name><surname>Brodin</surname><given-names>NP</given-names></name><name><surname>Santos</surname><given-names>MD</given-names></name><name><surname>Bazalova-Carter</surname><given-names>M</given-names></name><name><surname>Sawant</surname><given-names>A</given-names></name></person-group><article-title>A failure modes and effects analysis quality management framework for image-guided small animal irradiators: A change in paradigm for radiation biology</article-title><source>Med Phys</source><year>2020</year><volume>47</volume><issue>4</issue><fpage>2013</fpage><lpage>2022</lpage><pub-id pub-id-type="pmid">31986221</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hacker</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>EL</given-names></name><name><surname>Lefebvre</surname><given-names>TL</given-names></name><name><surname>Sweeney</surname><given-names>PW</given-names></name><name><surname>Bohndiek</surname><given-names>SE</given-names></name></person-group><article-title>Performance evaluation of mesoscopic photoacoustic imaging</article-title><source>Photoacoustics</source><year>2023</year><volume>31</volume><elocation-id>100505</elocation-id><pub-id pub-id-type="pmcid">PMC10199419</pub-id><pub-id pub-id-type="pmid">37214427</pub-id><pub-id pub-id-type="doi">10.1016/j.pacs.2023.100505</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>Andrew G</given-names></name><name><surname>Hartono</surname><given-names>Muhamad</given-names></name><name><surname>Ou</surname><given-names>Hui-Ling</given-names></name><name><surname>Popov</surname><given-names>Andrea BistroviÄ‡</given-names></name><name><surname>Brown</surname><given-names>Emma L</given-names></name><name><surname>Joseph</surname><given-names>James</given-names></name><name><surname>Golinska</surname><given-names>Monika</given-names></name><name><surname>GonzÃjlez-Gualda</surname><given-names>Estela</given-names></name><name><surname>Macias</surname><given-names>David</given-names></name><name><surname>Ge</surname><given-names>Jianfeng</given-names></name><name><surname>Denholm</surname><given-names>Mary</given-names></name><etal/></person-group><article-title>An indocyanine green-based nanoprobe for in vivo detection of cellular senescence</article-title><source>Angewandte Chemie International Edition</source><year>2024</year><volume>63</volume><issue>25</issue><elocation-id>e202404885</elocation-id><pub-id pub-id-type="pmcid">PMC11497227</pub-id><pub-id pub-id-type="pmid">38622059</pub-id><pub-id pub-id-type="doi">10.1002/anie.202404885</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartono</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>AG</given-names></name><name><surname>Else</surname><given-names>TR</given-names></name><name><surname>Evtushenko</surname><given-names>AS</given-names></name><name><surname>Bohndiek</surname><given-names>SE</given-names></name><name><surname>Munoz-Espin</surname><given-names>D</given-names></name><name><surname>Fruk</surname><given-names>L</given-names></name></person-group><article-title>Photoacoustic polydopamine-indocyanine green (pda-icg) nanoprobe for detection of senescent cells</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><elocation-id>29506</elocation-id><pub-id pub-id-type="pmcid">PMC11603024</pub-id><pub-id pub-id-type="pmid">39604512</pub-id><pub-id pub-id-type="doi">10.1038/s41598-024-79667-7</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozin</surname><given-names>SV</given-names></name><name><surname>Duda</surname><given-names>DG</given-names></name><name><surname>Munn</surname><given-names>LL</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><article-title>Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?</article-title><source>J Natl Cancer Inst</source><year>2012</year><volume>104</volume><issue>12</issue><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="pmcid">PMC3379722</pub-id><pub-id pub-id-type="pmid">22572994</pub-id><pub-id pub-id-type="doi">10.1093/jnci/djs239</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poleszczuk</surname><given-names>Jan</given-names></name><name><surname>Luddy</surname><given-names>Kimberly</given-names></name><name><surname>Chen</surname><given-names>Lu</given-names></name><name><surname>Lee</surname><given-names>Jae K</given-names></name><name><surname>Harrison</surname><given-names>Louis B</given-names></name><name><surname>Czerniecki</surname><given-names>Brian J</given-names></name><name><surname>Soliman</surname><given-names>Hatem</given-names></name><name><surname>Enderling</surname><given-names>Heiko</given-names></name></person-group><article-title>Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival</article-title><source>Breast Cancer Research</source><year>2017</year><volume>19</volume><issue>1</issue><fpage>75</fpage><pub-id pub-id-type="pmcid">PMC5493088</pub-id><pub-id pub-id-type="pmid">28666457</pub-id><pub-id pub-id-type="doi">10.1186/s13058-017-0870-1</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Jozsa</surname><given-names>F</given-names></name><name><surname>Douek</surname><given-names>M</given-names></name></person-group><article-title>A systematic review of neo-adjuvant radiotherapy in the treatment of breast cancer</article-title><source>Ecancermedicalscience</source><year>2021</year><volume>15</volume><elocation-id>1175</elocation-id><pub-id pub-id-type="pmcid">PMC7929768</pub-id><pub-id pub-id-type="pmid">33680089</pub-id><pub-id pub-id-type="doi">10.3332/ecancer.2021.1175</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Civil</surname><given-names>Yasmin A</given-names></name><name><surname>Jonker</surname><given-names>Lysanne W</given-names></name><name><surname>Groot Koerkamp</surname><given-names>Maartje PM</given-names></name><name><surname>Duvivier</surname><given-names>Katya M</given-names></name><name><surname>de Vries</surname><given-names>Ralph</given-names></name><name><surname>Oei</surname><given-names>Arlene L</given-names></name><name><surname>Slotman</surname><given-names>Berend J</given-names></name><name><surname>van der Velde</surname><given-names>Susanne</given-names></name><name><surname>Desiree van den Bongard</surname><given-names>HJG</given-names></name></person-group><article-title>Preoperative partial breast irradiation in patients with low-risk breast cancer: A systematic review of literature</article-title><source>Annals of Surgical Oncology</source><year>2023</year><volume>30</volume><issue>6</issue><fpage>3263</fpage><lpage>3279</lpage><pub-id pub-id-type="pmcid">PMC10175515</pub-id><pub-id pub-id-type="pmid">36869253</pub-id><pub-id pub-id-type="doi">10.1245/s10434-023-13233-9</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilski</surname><given-names>Mateusz</given-names></name><name><surname>Konat-Bąska</surname><given-names>Katarzyna</given-names></name><name><surname>Zerella</surname><given-names>Maria Alessia</given-names></name><name><surname>Corradini</surname><given-names>Stefanie</given-names></name><name><surname>Hetnał</surname><given-names>Marcin</given-names></name><name><surname>Leonardi</surname><given-names>Maria Cristina</given-names></name><name><surname>Gruba</surname><given-names>Martyna</given-names></name><name><surname>Grzywacz</surname><given-names>Aleksandra</given-names></name><name><surname>Hatala</surname><given-names>Patrycja</given-names></name><name><surname>Jereczek-Fossa</surname><given-names>Barbara Alicja</given-names></name><name><surname>Fijuth</surname><given-names>Jacek</given-names></name><etal/></person-group><article-title>Advances in breast cancer treatment: a systematic review of preoperative stereotactic body radiotherapy (sbrt) for breast cancer</article-title><source>Radiation Oncology</source><year>2024</year><volume>19</volume><issue>1</issue><fpage>103</fpage><pub-id pub-id-type="pmcid">PMC11295558</pub-id><pub-id pub-id-type="pmid">39095859</pub-id><pub-id pub-id-type="doi">10.1186/s13014-024-02497-4</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gertsenshteyn</surname><given-names>Inna</given-names></name><name><surname>Epel</surname><given-names>Boris</given-names></name><name><surname>Giurcanu</surname><given-names>Mihai</given-names></name><name><surname>Barth</surname><given-names>Eugene</given-names></name><name><surname>Lukens</surname><given-names>John</given-names></name><name><surname>Hall</surname><given-names>Kayla</given-names></name><name><surname>Martinez</surname><given-names>Jenipher Flores</given-names></name><name><surname>Grana</surname><given-names>Mellissa</given-names></name><name><surname>Maggio</surname><given-names>Matthew</given-names></name><name><surname>Miller</surname><given-names>Richard C</given-names></name><name><surname>Sundramoorthy</surname><given-names>Subramanian V</given-names></name><etal/></person-group><article-title>Absolute oxygen-guided radiation therapy improves tumor control in three preclinical tumor models</article-title><source>Frontiers in Medicine</source><year>2023</year><fpage>10</fpage><pub-id pub-id-type="pmcid">PMC10613495</pub-id><pub-id pub-id-type="pmid">37904839</pub-id><pub-id pub-id-type="doi">10.3389/fmed.2023.1269689</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><title>Study Design.</title><p>A) The human cell lines MCF7, a luminal A subtype ER+ and PR+ breast cancer model, and MDA-MB-231, a triple negative basal B subtype breast cancer model, were selected based on their differences in aggressiveness and radioresistance (<xref ref-type="bibr" rid="R47">47</xref>–<xref ref-type="bibr" rid="R50">50</xref>). B) Intratumoural features of cancer, such as hypoxia, induce radiation therapy resistance, and the vasculature, being the principal input of molecular oxygen, plays a key role in tumour oxygenation. C) Tumour vasculature can be imaged using photoacoustic imaging, in a tomographic configuration for functional analysis of oxygenation (upper panel), or in a planar raster-scanning configuration at the meso-scale for morphological vascular characterisation (lower panel). D) Study timeline with breast cancer models enrolled into either the control group, or one of the treated groups, <italic>i.e.</italic>, hypofractionated radiation therapy (HFRT) with 5 Gy per fraction delivered in 5 fraction, or single dose radiation therapy (SDRT) with 20 Gy delivered in a single fraction. E) Treatment simulation on cone-beam computed tomography with a single beam delivered in a moving arc. F) Timeline of imaging and radiation delivery in each treated group, with imaging conducted 24h before, 24h after radiation therapy, and at endpoint (7 days following treatment on average). Created with Biorender.com.</p></caption><graphic xlink:href="EMS206122-f001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><title>Evaluation of radiotherapy response in the preclinical breast cancer models.</title><p>Differences in response to selected radiation therapy schemes in the two breast cancer xenografts were assessed with tumour volume and <italic>ex vivo</italic> immunohistochemistry in resected tumours at endpoint. Growth curves assessed by calliper measurements in A) MCF7 and B) MDA-MB-231 models for the untreated (Control), hypofractionated (HFRT)-treated, and single dose (SDRT)-treated groups. Full lines represent average group-wise spline-fitted growth curves, shaded areas are 90% confidence intervals, and dashed lines represent the average enrolment size of 400 mm<sup>3</sup>. C) Percent change in measured tumour volume between enrolment and endpoint (7 days on average post-radiation therapy) demonstrating growth inhibition in all treatment groups. <italic>Ex vivo</italic> immunohistochemistry sections for D) proliferation on Ki67, quantified in E) bar and point plots, and F) DNA damage on <italic>γ</italic>-H2AX, quantified in G) bar and point plots, with bars representing mean and 90% confidence intervals. Scale bar, 200 μm. *<italic>P &lt; 0.05, **P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001.</p></caption><graphic xlink:href="EMS206122-f002"/></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><title>Differences in tumour vasculature and hypoxia after radiation therapy in breast cancer xenografts assessed with <italic>ex vivo</italic> immunohistochemistry.</title><p><italic>Ex vivo</italic> immunohistochemistry sections quantified for A) double CD31-ASMA representing mature vasculature coverage (with ASMA sections displayed) in B) bar and point plots, and C) hypoxia on HIF1-<italic>α</italic> in D) bar and point plots, with bars representing mean and 90% confidence intervals. Scale bar, 200 μm. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001.</p></caption><graphic xlink:href="EMS206122-f003"/></fig><fig id="F4" position="float"><label>Fig. 4</label><caption><title>Tomographic PAI delineates models based on intratumoural blood content and oxygenation at baseline.</title><p>A) Exemplar MCF7 and MDA-MB-231 tumour-bearing mice imaged at baseline (enrolment) with multispectral tomographic PAI, overlaid with quantitative parametric maps (from left to right) of sO<sub>2</sub>, and in response to a breathing gas challenge, ΔsO<sub>2</sub> and responding fraction. Scale bars, 2 mm. Bar plots of B) total haemoglobin, C) blood oxygen saturation (sO<sub>2</sub>) D) spatial standard deviation (SD) of sO<sub>2</sub>, E) ΔsO<sub>2</sub> under gas challenge, and F) responding fraction where each point represents an independent tumour. G) Correlation heatmap of <italic>in vivo</italic> tomographic PAI quantitative biomarkers and <italic>ex vivo</italic> immunohistochemistry parameters. H) Summary schematic of vascular microenvironment assessment using baseline tomographic PAI biomarkers in both models. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001. Created with BioRender.com.</p></caption><graphic xlink:href="EMS206122-f004"/></fig><fig id="F5" position="float"><label>Fig. 5</label><caption><title>Mesoscopic PAI detects underpinning differences in vascular density and architecture.</title><p>A) MCF7 and MDA-MB-231 tumour-bearing mice imaged at baseline (enrolment) showing (from left to right) mesoscopic PAI signal intensity, depth-resolved segmented vasculature and a skeletonised diameter map. Scale bars, 2 mm. Bar plots of B) mesoscopic PAI vascular density and C) number of connected components across the vascular networks. D) Correlation heatmap of <italic>in vivo</italic> mesoscopic PAI quantitative biomarkers and <italic>ex vivo</italic> immunohistochemistry parameters. E) Summary schematic of vascular microenvironment assessment using baseline mesoscopic PAI biomarkers in both models. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001. Created with BioRender.com.</p></caption><graphic xlink:href="EMS206122-f005"/></fig><fig id="F6" position="float"><label>Fig. 6</label><caption><title>Longitudinal <italic>in vivo</italic> tomographic photoacoustic imaging detects radiotherapy response in breast cancer models.</title><p>Exemplar blood oxygen saturation tumour maps with paired density plots in A) MCF7 and B) MDA-MB-231 xenografts, across time-points and treatment groups. Scale bar, 2 mm. Tomographic photoacoustic imaging biomarkers normalised to pre-treatment scan in MCF7 and MDA-MB-231 tumour-bearing mice, respectively, C,D) total haemoglobin (THb), and E,F) blood oxygen saturation (sO<sub>2</sub>). *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001.</p></caption><graphic xlink:href="EMS206122-f006"/></fig><fig id="F7" position="float"><label>Fig. 7</label><caption><title>Longitudinal <italic>in vivo</italic> mesoscopic photoacoustic imaging of treatment response in breast cancer models.</title><p>Exemplar maximal intensity projections of vascular networks on photoacoustic mesoscopy in A) MCF7 and B) MDA-MB-231 xenografts, across time-points and treatment groups. Scale bar, 4 mm. Mesoscopic photoacoustic imaging biomarkers normalised to pre-treatment scan in MCF7 and MDA-MB-231 tumour-bearing mice, respectively, C,D) blood volume (BV), E,F) vascular density, and G,H) looping structures. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001.</p></caption><graphic xlink:href="EMS206122-f007"/></fig><fig id="F8" position="float"><label>Fig. 8</label><caption><title>Conceptual schematic of reported PAI biomarkers for radiation response assessment in the tumour vascular microenvironment of breast cancer models.</title><p>A) PAI biomarkers 24h pre-RT are predictive of response in terms of endpoint change in volume, DNA damage, and proliferation; B) and remain predictive and identify early response 24h post-RT. C) Endpoint imaging reveals the vascular response to RT with endothelial cell apoptosis leading to microvascular disruption, identified as a decreased loop count and overall blood volume. D) Potential use of PAI within the neoadjuvant RT framework, at baseline for profiling tumour radiosensitivity, for mapping intratumoural oxygenation to enable dose painting and further adaptation over the course of treatment, the ability to detect and predict response, and value in confirming response following treatment completion for improved tumour resectability guidance. Note: sO<sub>2</sub>, blood oxygen saturation; RF, responding fraction; THb, total haemoglobin; BV, blood volume; PAI, photoacoustic imaging; RT, radiation therapy. Created with BioRender.com.</p></caption><graphic xlink:href="EMS206122-f008"/></fig></floats-group></article>